darunavir has been researched along with HIV Coinfection in 681 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 137 (20.12) | 29.6817 |
| 2010's | 427 (62.70) | 24.3611 |
| 2020's | 117 (17.18) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Dawson, ZL; Ghosh, AK; Mitsuya, H | 1 |
| Ghosh, AK | 1 |
| Brynda, J; Kagan, RM; Konvalinka, J; Kozísek, M; Rezácová, P; Sasková, KG; Yashina, T | 1 |
| Bodem, J; Buchholz, B; Henke, S; Jacobs, GB; Konvalinka, J; Kozísek, M; Kräusslich, HG; Müller, V; Rezácová, P; Sasková, KG; Schuch, A | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Shen, CH; Weber, IT; Yashchuk, S | 1 |
| Agniswamy, J; Aoki, M; Bulut, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Rao, KV; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Brindisi, M; Ella-Menye, JR; Ghosh, AK; Mitsuya, H; Nyalapatla, PR; Takayama, J; Wang, YF; Weber, IT; Yashchuk, S | 1 |
| Agrawal, N; Chmielewski, J; Hrycyna, CA; Lan, J; Rowe, J; Yu, Q | 1 |
| Cen, S; Dong, B; Guo, Y; Liang, C; Ma, L; Wang, J; Wang, Y; Wang, Z; Wen, J; Zhang, G; Zhou, J; Zhu, M | 1 |
| Ali, A; Henes, M; Kosovrasti, K; Kurt Yilmaz, N; Lee, SK; Lockbaum, GJ; Nalivaika, EA; Rao, DN; Rusere, LN; Schiffer, CA; Spielvogel, E; Swanstrom, R | 1 |
| Cen, S; Dong, B; Ma, L; Wang, J; Wang, Y; Zhang, G; Zhou, J; Zhu, M | 1 |
| Balogh, A; Bidner, H; Boesecke, C; Cordes, C; Heiken, H; Krznaric, I; Kümmerle, T; Schneider, J; Spinner, CD; Stellbrink, HJ; Wolf, E | 1 |
| Arduino, I; Curri, ML; Denora, N; Depalo, N; Fanizza, E; Laquintana, V; Latronico, T; Liuzzi, GM; Mastroianni, CM; Milella, S; Panniello, A; Rizzi, F; Striccoli, M | 1 |
| Ipte, PR; Manna, S; Sahoo, S; Satpati, AK | 1 |
| Ajana, F; Avettand-Fenoel, V; Bauer, R; Charre, C; Cheret, A; Cua, E; Gardiennet, E; Lacombe, K; Mariaggi, AA; Meiffredy, V; Meyer, L; Pialoux, G; Rouzioux, C | 1 |
| Ahsan, M; Pindi, C; Senapati, S | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Castagna, A; Comi, L; Di Filippo, E; Fumagalli, L; Galli, L; Gianotti, N; Maggiolo, F; Nozza, S; Rizzi, M; Valenti, D | 2 |
| Abu Khattab, M; Al Maslamani, M; Al Soub, H; Al-Khal, A; Alibrahim, R; Elmekaty, EZI; Elsayed, A; Eltaib, S; Hassanin, R; Mohamed Ibrahim, MI; Rustom, F | 1 |
| Akpomiemie, G; Christofides, N; Lalla-Edward, S; Machisa, M; Mokgethi, NO | 1 |
| Bungau, SG; Marin, RC; Moleriu, LC; Streinu-Cercel, A | 1 |
| Bonnet, F; Burkholder, G; Castagna, A; Cavassini, M; Cichon, P; Crane, H; Domingo, P; Gill, MJ; Grabar, S; Guest, J; Ingle, SM; Obel, N; Psichogiou, M; Rava, M; Reiss, P; Rentsch, CT; Riera, M; Sabin, CA; Schuettfort, G; Silverberg, MJ; Smith, C; Stecher, M; Sterling, TR; Sterne, JAC; Trickey, A; Zhang, L | 1 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Byakika-Kibwika, P; Chappell, CA; Fletcher, CV; Jeppson, J; Kaboggoza, J; Kyohairwe, I; Lamorde, M; Mbabazi, L; Musaazi, J; Nakalema, S; Nakijoba, R; Nassiwa, S; Pham, M; Scarsi, KK; Siccardi, M; Walimbwa, SI; Winchester, L | 1 |
| Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M | 1 |
| Aebi-Popp, K; Crisinel, PA; Decosterd, L; Duppenthaler, A; Hoesli, I; Kahlert, CR; Martinez De Tejada, B; Marzolini, C; Rauch, A; Saldanha, SA | 1 |
| Ali, S; Bayserkin, B; Dzissyuk, N; Issanov, A; Mukhatayev, Z; Mukhatayeva, A; Mustafa, A; Vermund, SH | 1 |
| Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L | 1 |
| Campisi, J; Desprez, PY; Hughes, JB; Kuehnemann, C; Melov, S; Wiley, CD | 1 |
| Cuéllar-Monreal, MJ; Monte-Boquet, E; Montero, M; Pérez-Huertas, P; Poveda-Andrés, JL; Salavert, M; Solana-Altabella, A | 1 |
| Brunet, L; Dunbar, M; Fusco, GP; Fusco, JS; McCurdy, LH; McNicholl, IR; Mounzer, K; Sension, M | 1 |
| Bungau, SG; Marin, RC; Moleriu, RD; Negru, PA; Radu, AF; Tit, DM | 1 |
| Abdalla, S; Coelho, A; Compagnucci, A; Cressey, TR; Hirt, D; Ramos, JT; Riault, Y; Saidi, Y; Tréluyer, JM; Zheng, Y | 1 |
| Anderson, D; Bushen, J; Cai, J; Dunn, K; Luo, D; Simonson, RB | 1 |
| Ali, A; Henes, M; Kosovrasti, K; Lee, SK; Lockbaum, GJ; Nalivaika, EA; Schiffer, CA; Sondgeroth, A; Spielvogel, E; Swanstrom, R; Yilmaz, NK; Zhou, S | 1 |
| Borghetti, A; Borghi, V; Bruzzone, B; Callegaro, A; Ciccullo, A; Di Biagio, A; Di Giambenedetto, S; Farinacci, D; Gennari, W; Rusconi, S; Salvo, PF; Saracino, A; Vicenti, I; Zazzi, M | 1 |
| Antinori, S; Cattaneo, D; Gervasoni, C; Gori, A; Micheli, V; Pagano, S | 1 |
| Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Colafigli, M; Di Giambenedetto, S; Fabbiani, M; Farinacci, D; Lagi, F; Masini, M; Montagnani, F; Mussini, C; Panza, F; Rossetti, B; Sterrantino, G; Tumbarello, M | 1 |
| Bruzzone, B; Castagna, A; Di Biagio, A; Labate, L; Santoro, MM; Spagnuolo, V; Zazzi, M | 1 |
| Avettand-Fenoel, V; Brunet-Cartier, C; Bui, E; Canestri, A; Chabrol, A; Chambrin, V; Delmas, S; Frange, P; Le Chenadec, J; Mandelbrot, L; Marchand, L; Morlat, P; Paul, C; Peretti, D; Peytavin, G; Sibiude, J; Simon-Toulza, C; Tubiana, R; Warszawski, J | 1 |
| Ambe Chenwi, C; Angong Beloumou, G; Dambaya, B; Djupsa Ndjeyep, SC; Fokam, J; Ka'e, AC; Kouanfack, C; Mbopi Keou, FX; Mbouyap, PR; Mossiang, L; Ndjolo, A; Ngoufack Jagni Semengue, E; Nka, AD; Takou, D; Teto, G | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Ariyawansa, J; Palmer, M; Van Hemelryck, S; Van Landuyt, E; Vanveggel, S | 1 |
| Cohen, CE; Garvey, L; Heskin, J; Leung, S; Naous, N; Oddie, PD | 1 |
| Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG | 1 |
| Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
| Brites, C; Netto, EM; Patiño Escarcina, JE | 1 |
| Adeojo, L; Brooks, KM; Bunn, HT; George, JM; Kovacs, JA; Kumar, P; Pau, AK; Peloquin, CA; Swaim, D | 1 |
| Brunel, V; Malval, B; Massy, N | 1 |
| Angioni, G; Bonfanti, P; Calza, L; Cascio, A; De Socio, GV; Dentone, C; Di Biagio, A; Madeddu, G; Maggi, P; Menzaghi, B; Pellicanò, GF; Ricci, E; Squillace, N; Taramasso, L; Valsecchi, L | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Alves Saldanha, S; Battegay, M; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Beum, R; Gardner, EM; Hawkins, KL; Johnson, S; McLees, MP; Montague, BT; Rowan, SE | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Ahagon, CM; Brígido, LFM; Cabral, GB; Coelho, LPO; Ferreira, JLP; Lopes, GISL; Ribeiro, IC; Soldi, GFR | 1 |
| Alejos, B; Boix, V; Garcia-Fraile, L; Gonzalez-Cordon, A; Gonzalez-Domenech, CM; Gutierrez, M; Knobel, H; Lozano, F; Martin-Carbonero, L; Martinez, E; Montero, M; Moreno, A; Negredo, E; Ocampo, A; Payeras, A; Perez-Elias, MJ; Sanz, J; Torralba, M | 1 |
| Anglaret, X; Anzian, A; Bado, G; Benalycherif, A; Chaix, ML; Cisse, M; Congo-Ouedraogo, M; de Monteynard, LA; Diallo, I; Diallo, M; Drabo, J; Eholie, SP; Ello, F; Gabassi, A; Gabillard, D; Girard, PM; Karcher, S; Landman, R; Le Carrou, J; Maiga, AI; Messou, E; Minta, DK; Moh, R; Peytavin, G; Sangaré, L; Sawadogo, A; Seydi, M; Toni, TD; Toure-Kane, C; Zoungrana, J | 1 |
| Brizzi, MB; Chiampas, TD; Novak, RM | 1 |
| Barber, TJ; Spinner, CD | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K | 1 |
| Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V | 1 |
| Castro, A; Clavero, E; Díaz-Díaz, JL; Mena, A | 1 |
| Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L | 1 |
| Mejias, A; Peeples, ME; Ramilo, O; Teng, MN | 1 |
| Allavena, C; Cheret, A; Cotte, L; Delobel, P; Duvivier, C; Goujard, C; Lascoux Combe, C; Meyer, L; Poizot-Martin, I; Rey, D; Reynes, J; Seng, R; Surgers, L; Tran, L; Veil, R | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Kourkounti, S; Paparizos, V; Vasalou, V | 1 |
| Boccara, F; Costagliola, D; Cotte, L; de Castro, N; Duval, X; Duvivier, C; Grabar, S; Katlama, C; Lang, S; Mary-Krause, M; Partisani, M; Potard, V; Raffi, F; Ronot-Bregigeon, S; Simon, A; Tattevin, P; Weiss, L; Zucman, D | 1 |
| Siedner, MJ; Triant, VA | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Best, BM; Capparelli, EV; Chakhtoura, N; Eke, AC; Kreitchmann, R; Mirochnick, M; Shapiro, DE; Smith, E; Stek, AM; Wang, J | 1 |
| Ebrahim, I; Maartens, G; McIlleron, H; Orrell, C; Smythe, W; Wiesner, L | 1 |
| Bailey, AC; Mackie, N; Muir, D; Ring, K | 1 |
| Caldwell, A; Cuppone, AM; Dereuddre-Bosquet, N; Desjardins, D; Frank, B; Grand, RL; Gwozdz, G; Hijazi, K; Iannelli, F; Kelly, C; Mukhopadya, I; Pozzi, G; Santoro, F; Scala, C; Smith, KA | 1 |
| Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M | 1 |
| Antinori, A; Bonora, S; Castelli, F; Cattelan, AM; Cauda, R; Celesia, BM; Cossu, MV; d'Arminio Monforte, A; Gianotti, N; Gori, A; Mancusi, D; Manzillo, E; Maserati, R; Menzaghi, B; Orofino, G; Ripamonti, D; Rucci, F; Rusconi, S; Santantonio, TA; Savinelli, S; Sterrantino, G; Stingone, C; Termini, R; Uglietti, A; Vergori, A | 1 |
| Bernardino, JI; Casado, JL; Colomer, J; Curran, A; Domingo, P; González-Cordón, A; Llibre, JM; Martínez, E; Navarro, J; Portilla, J; Rial-Crestelo, D; Ribera, E; Vizcarra, P | 1 |
| Blanco, JL; Cabello, A; Casado, JL; Deltoro, MG; Diaz De Santiago, A; Espinosa, N; Galindo, MJ; Lopez, JC; Mena, A; Montejano, R; Montero, M; Negredo, E; Palacios, R; Vergas, J; Vizcarra, P | 1 |
| Burger, DM; Calmy, A; Marzolini, C | 1 |
| Cottrell, ML; Deeks, SG; Hatano, H; Hoh, R; Hunt, PW; Kashuba, ADM; Lee, SA; Liegler, TJ; Savic, RM; Somsouk, M; Stephenson, S; Telwatte, S; Yukl, S | 1 |
| Antinori, A; Cavellec, M; de Wit, S; Gaultier, A; Jessen, H; Le Thuaut, A; Molina, JM; Ningre, M; Pozniak, A; Raffi, F; Soria, A | 1 |
| Cattaneo, D; Gervasoni, C; Giacomelli, A; Mancon, A; Micheli, V | 1 |
| Antinori, A; Aprea, L; Castagna, A; Cattelan, A; Cossu, MV; D'Ettore, G; Di Cristo, V; Ferrara, S; Focà, E; Gori, A; Locatelli, ME; Madeddu, G; Mancusi, D; Menzaghi, B; Orofino, G; Pontali, E; Rossetti, B; Rucci, F; Scerbo, P; Squillace, N; Sterrantino, G; Termini, R; Uglietti, A; Valenti, D | 1 |
| Bernacchia, D; Cattaneo, D; Conti, F; Gervasoni, C; Lupo, A; Merli, S; Pezzati, L; Riva, A; Rusconi, S; Siano, M; Sollima, S | 1 |
| Bickel, M; Gillor, D; Grunwald, S; Härter, G; Hoffmann, C; Krznaric, I; Mueller, MC; Müller, M; Postel, N; Roider, J; Römer, K; Schabaz, F; Schewe, K; Spinner, CD | 1 |
| Blanch-Lombarte, O; Clotet, B; Jiménez-Moyano, E; Paredes, R; Peña, R; Prado, JG; Santos, JR | 1 |
| Aoki, M; Aoki-Ogata, H; Bulut, H; Das, D; Davis, DA; Ghosh, AK; Hattori, SI; Hayashi, H; Mitsuya, H; Nyalapatla, PR; Rao, KV | 1 |
| Balogh, A; Bidner, H; Boesecke, C; Klinker, HHF; Schneider, J; Spinner, CD; Weidlich, S; Wolf, E; Zink, A | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Belkhir, L; Elens, L; Haufroid, V; Stillemans, G; Vandercam, B; Vincent, A | 2 |
| Cen, S; Dong, B; Ma, L; Wang, J; Wang, Y; Zhang, G; Zhou, H; Zhou, J; Zhu, M | 1 |
| DeJesus, E; Hinestrosa, F; Marquez, O; Nguyen, V; Rolle, CP | 1 |
| Brígido, LFM; de Miranda, ÉJFP; Juliato, D; Lopes, GISL; Martins, AP; Santos, AMRD; Vidal, JE | 1 |
| Acosta, S; Dunk, C; Kala, S; Serghides, L | 1 |
| Devanathan, AS; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kashuba, ADM; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, M; Neo, DT; Robertson, K; Schmitz, JL; Sebastian, J; Shaheen, NJ | 1 |
| Cauldbeck, H; Elkateb, H; McDonald, T; Niezabitowska, E; Owen, A; Rannard, S; Tatham, LM | 1 |
| Beloumou, G; Billong, SC; Bissek, AZ; Cham, F; Colizzi, V; Dambaya, B; Elat, JN; Etame, MMN; Fokam, J; Kamgaing, N; Kamgaing, R; Mossiang, L; Moudourou, S; Moussi, EE; Nanfack, AJ; Ndjolo, A; Ngako Pamen, JN; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Temgoua, ES; Teto, G | 1 |
| Biasizzo, J; Cojutti, PG; Della Siega, P; Fabris, M; Givone, F; Londero, A; Pea, F; Tascini, C | 2 |
| Boffito, M; Girometti, N; Lander, F; McOwan, A; Nwokolo, N; Whitlock, G | 1 |
| Adrian, S; Beghetto, B; Erlandson, KM; Feng, H; Guaraldi, G; Lake, JE; Ligabue, G; Miao, H; Milic, J; Nardini, G; Roncaglia, E; Scherzinger, A | 1 |
| Chan, WW; Li, M; Zucker, SD | 1 |
| Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ | 1 |
| Ballivian, J; Cassetti, I; Cecchini, DM; Huberman, M; Rombini, F; Urueña, A | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Blanche, S; Chetty, P; Hufkens, V; Masenya, M; Opsomer, M; Vanveggel, S; Violari, A | 1 |
| Cazzaniga, A; Galli, M; Maier, J; Rusconi, S; Scrimieri, R | 1 |
| Devi Singh, V; Kumar Singh, V | 1 |
| Al-Majed, AA; Alsaif, NA; Alzaid, A; Bakheit, AH; Darwish, IA; Herqash, RN | 1 |
| Antinori, A; Armenia, D; Berno, G; Borghi, V; Bouba, Y; Ceccherini-Silberstein, F; Cicalini, S; Fabeni, L; Gagliardini, R; Mussini, C; Perno, CF; Santoro, MM; Vergori, A | 1 |
| Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K | 1 |
| Alejos, B; Boix, V; Crespo, M; De La Fuente Moral, S; De La Torre Lima, J; De Los Santos Gil, I; Galindo, MJ; Gutierrez, MM; Lozano, F; Martinez, E; Montero-Alonso, M; Palacios, R; Payeras Cifre, A; Perez Elias, MJ; Ribera, E; Sanz, J | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Andersson, LM; Edén, A; Eriksen, J; Gisslén, M; Mellgren, Å; Nilsson, S; Thalme, A; Treutiger, CJ; Tyrberg, E | 1 |
| Cohen, J; Eckardt, P; Mohan, A; Sherman, EM; Tijmes, S | 1 |
| Eche, S; Gordon, ML; Kumar, A; Sonela, N | 1 |
| Cattaneo, D; Corbellino, M; Cozzi, V; Fusi, M; Gervasoni, C | 1 |
| Boesecke, C; Bührlen, B; Cordes, C; Fischer, F; Heiken, H; Jensen, BE; Krznaric, I; Kümmerle, T; Olliges, E; Ronel, J; Schneider, J; Scholten, S; Spinner, CD; Stellbrink, HJ; Weidlich, S; Wolf, E | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Hatleberg, CI; Ryom, L; Sabin, C | 1 |
| Best, BM; Burchett, S; Capparelli, EV; Chakhtoura, N; Denson, K; Febo, IL; George, K; Mirochnick, M; Momper, JD; Paul, ME; Rungruengthanakit, K; Scott, GB; Shapiro, DE; Smith, E; Stek, A; Wang, J; Yang, DZ | 1 |
| Boix, V; Dash, PK | 1 |
| Chen, L; He, G; Jia, Y; Tian, X; Wang, K; Yao, Y | 1 |
| Gordon, M; Marie, V | 1 |
| Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Capetti, A; Cattaneo, D; Clementi, E; Cozzi, V; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Kurt Yilmaz, N; Leidner, F; Paulsen, JL; Ragland, DA; Schiffer, CA | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Bayés-Genís, A; Blanco, J; Bonjoch, A; Clotet, B; Echeverría, P; Gómez-Mora, E; Negredo, E; Pérez-Alvarez, N; Puig, J; Roura, S | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Antoniou, T; Bayoumi, AM; Burchell, AN; Cooper, C; Hogg, RS; Klein, MB; Loutfy, M; Machouf, N; Montaner, JS; Raboud, J; Szadkowski, L; Tsoukas, C; Walmsley, S; Wong, A | 1 |
| Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A | 1 |
| Brown, K; Liu, C; Nettles, RE; Patel, M; Patterson-Browning, B; Stewart, L | 1 |
| Amara, A; Boffito, M; Elliot, ER; Else, L; Higgs, C; Khoo, S; Moyle, G; Pagani, N; Schoolmeesters, A | 1 |
| Fujiwara, H; Hasegawa, N; Kato, S; Takagi, R; Tanabe, Y; Yamada, E | 1 |
| Antinori, A; Bonora, S; Carbone, A; Cozzi-Lepri, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Gianotti, N; Madeddu, G; Rusconi, S | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Harper, KN | 1 |
| Bartels, H; Battegay, M; Decosterd, L; Marzolini, C | 1 |
| Chatelut, E; Delobel, P; Gandia, P; Metsu, D; Toutain, PL | 1 |
| Cory, TJ; Gong, Y; Kumar, S; Li, J; Li, W; Meibohm, B; Midde, NM | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Alffenaar, JC; Bierman, WFW; Daskapan, A; de Weerd, DA; Dijkema, D; Kosterink, JGW; Stienstra, Y; van der Werf, TS | 1 |
| Guaraldi, G; Raggi, P | 1 |
| Bregigeon, S; Canet, B; Cano, CE; Cloarec, N; Ladaique, A; Poizot-Martin, I; Solas, C; Tamalet, C; Zaegel-Faucher, O | 1 |
| Boesecke, C; Degen, O; Klinker, HHF; Krznaric, I; Kümmerle, T; Schwerdtfeger, C; Spinner, CD; Wolf, E; Zink, A | 1 |
| Desai, J; Thakkar, H | 1 |
| Baldin, GM; Barbarini, G; Capetti, AF; Cattelan, AM; Cenderello, G; Cossu, MV; De Socio, GV; Niero, FP; Orofino, G; Riccardi, N; Rizzardini, G; Rusconi, S; Soria, A; Sterrantino, G | 1 |
| Kashuba, A; Pope, R | 1 |
| Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Alffenaar, JC; Bierman, WFW; Daskapan, A; Kosterink, JGW; Stienstra, Y; Touw, DJ; van der Werf, TS | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Joly, V; Landman, R; Marcelin, AG; Perrier, M; Todesco, E; Visseaux, B; Yazdanpanah, Y | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N | 1 |
| Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W | 1 |
| Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M | 1 |
| Back, D; Boffito, M; Devitt, E; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Pozniak, A | 1 |
| Assoumou, L; Caby, F; Calin, R; Katlama, C; Lê, MP; Marcelin, AG; Nguyen, T; Peytavin, G; Schneider, L; Seang, S; Soulie, C; Tubiana, R; Valantin, MA | 1 |
| Lundgren, J; Mocroft, A; Ryom, L | 1 |
| Challenger, E; Clotet, B; Curran, A; Khoo, S; Miranda, C; Moltó, J; Ribera, E; Santos, JR; Valle, M | 1 |
| Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B | 1 |
| Alonso, J; Barber, TJ; Boffito, M; Davies, N; Fortuny, R; Gazzard, B; Imaz, A; Mandalia, S; Niubó, J; Podzamczer, D; Pozniak, A | 1 |
| Bonnal, C; Descamps, D; Desselas, E; Giraud, J; Lariven, S; Le Meur, L; Lê, MP; Lillo-Le-Louet, A; Massias, L; Peytavin, G; Sonneville, R; Tantet, C; Yazdanpanah, Y | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| Avettand-Fenoel, V; Cheret, A; Hirt, D; Meyer, L; Morlat, P; Naqvi, A; Pressiat, C; Rouzioux, C; Tran, L; Treluyer, JM; Viard, JP; Zheng, Y | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Chen, CN; Lalonde, RG; Landry, S; Patel, N; Sanche, S; Sheehan, NL; Thibeault, D; Tseng, A | 1 |
| Bastiaans, DET; Burger, DM; Colbers, APH; Geelen, SPM; Roukens, M; van der Flier, M; van Rossum, AMC; Vermont, CL; Visser, EG | 1 |
| Ángel-Moreno Maroto, A; de la Fuente Moral, S; Díaz de Santiago, A | 1 |
| Aoki, M; Aoki-Ogata, H; Das, D; Ghosh, AK; Hayashi, H; Mitsuya, H; Takamatsu, Y | 1 |
| Becker, M; Chan, S; Harrigan, PR; Kasper, K; Keynan, Y; Wheeler, J | 1 |
| Cevik, M; Orkin, C | 1 |
| Antinori, A; Lazzarin, A; Mancusi, D; Palma, M; Termini, R; Uglietti, A | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S; Rigo, F | 1 |
| De Wit, S; Demeester, R; Florence, E; Goffard, JC; Moutschen, M; Piryns, H; Thilakarathne, P; Van Wijngaerden, E; Vandekerckhove, L; Vandercam, B | 1 |
| Blanco, J; Clotet, B; Gómez-Mora, E; Hernández-Rodríguez, A; Marfil, S; Martínez-Bonet, M; Martinez-Picado, J; Matas, L; Moltó, J; Morón-López, S; Muñoz-Fernández, MA; Puertas, MC; Santos, JR; Urrea, V | 1 |
| Castilla, JA; Gonzalvo, MC; Hidalgo, C; López-Ruz, MA; López-Zúñiga, MA; Pasquau, J; Rosario, J; Sampedro, A | 1 |
| Araki, T; Gohda, F; Handa, H; Nagano, D; Nakamura, T; Ogawa, Y; Uchiumi, H; Yamamoto, K; Yanagisawa, K | 1 |
| Arzi, RS; Ashkenazi, DL; Augustine, R; Shofti, R; Sosnik, A; Zlobin, V | 1 |
| d' Arminio Monforte, A; Dabis, F; De Wit, S; El-Sadr, W; Fontas, E; Hatleberg, CI; Kirk, O; Law, M; Lundgren, JD; Mocroft, A; Phillips, A; Reiss, P; Ryom, L; Sabin, C; Weber, R | 1 |
| Clotet, B; Negredo, E | 1 |
| Bouteloup, V; Calvez, V; Flandre, P; Girard, PM; Grude, M; Izopet, J; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Moinot, L; Morand-Joubert, L; Valantin, MA | 1 |
| Chaix, ML; Chevret, S; Delobel, P; Desseaux, K; El Abbassi, EM; Gallien, S; Katlama, C; Madelaine, I; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Valin, N | 1 |
| Bertrand, J; Chaix, ML; Chevret, S; Delobel, P; El Abbassi, EMB; Gallien, S; Katlama, C; Lê, MP; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Yazdanpanah, Y | 1 |
| Ellis, RJ; Gouaux, B; Letendre, SL; Levine, AJ; Moore, DJ; Soontornniyomkij, B; Soontornniyomkij, V; Umlauf, A | 1 |
| Castagna, A; Lazzarin, A; Spagnuolo, V | 1 |
| Deeks, ED | 3 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Höring, S; Löffler, B; Pletz, MW; Rößler, S; Schleenvoigt, BT; Weis, S | 1 |
| Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Boven, K; Brown, K; Chavers, S; Dimitrova, D; Luo, D; Mehbob, A; Moecklinghoff, C; Nettles, RE; Opsomer, M; Pai, H; Purrington, A; Vanveggel, S; Verspeelt, J | 1 |
| Baettig, V; Battegay, M; Courlet, P; Delko, T; Marzolini, C | 1 |
| Duggan, JM; Sahloff, EG | 1 |
| Brogan, AJ; Davis, AE; Goodwin, B | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Cabot, JF; Denault, JS; Langlois, H; Marcotte, S; Sheehan, NL | 1 |
| Chaix, ML; Chevret, S; Delobel, P; Gallien, S; Katlama, C; Lê, MP; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Yazdanpanah, Y | 1 |
| Antinori, A; Carrara, S; Cozzi Lepri, A; D'arminio Monforte, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Giacometti, A; Lichtner, M; Marchetti, G; Sighinolfi, L | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Alffenaar, JC; Bierman, WFW; Cattaneo, D; Daskapan, A; Gervasoni, C; Kosterink, JGW; Proost, JH; Resnati, C; Stienstra, Y; Touw, DJ; Tran, QTD; van der Werf, TS | 1 |
| Martìnez, E; Pulido, F | 1 |
| Gómez Ayerbe, C; Palacios Muñoz, R; Santos González, J | 1 |
| Galindo Puerto, MJ | 2 |
| Llibre, JM | 1 |
| Fontecha, M; Luis Casado, J; Monsalvo, M; Vizcarra, P | 1 |
| Castro, Á; Cid, P; Dueñas, C; Garcinuño, MÁ; Grande, C; Lorenzo, JF; Margusino, L; Mena, Á; Quiñones, M; Rodríguez-Osorio, I | 1 |
| Cattaneo, D; Cheli, S; Clementi, E; Fusi, M; Gervasoni, C | 1 |
| Bociąga-Jasik, M; Cielniak, I; Firląg Burkacka, E; Gąsiorowski, J; Horban, A; Jabłonowska, E; Kalinowska, A; Piątek, A; Siwak, E; Wójcik-Cichy, K | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Tzonev, R; Yancheva, N | 1 |
| Avramovic, G; Else, LJ; Jackson, V; Khoo, SH; Kuan, KB; Lambert, JS; Lawler, M; Le Blanc, D; McDonald, G; Murtagh, R; Patel, A; Redmond, N | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Moreno, A; Rodriguez-Sagrado, MA; Vivancos, MJ | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Borghetti, A; Canovari, B; Ciccullo, A; Colafigli, M; Colangeli, V; De Luca, A; Di Biagio, A; Di Giambenedetto, S; DʼArminio Monforte, A; Francisci, D; Gagliardini, R; Lamonica, S; Latini, A; Mastroianni, C; Mezzaroma, I; Orofino, G; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V | 1 |
| Arazo, P; Carmena, J; Crusells, MJ; de Jesus, SE; de la Torre, J; Galindo, MJ; Hidalgo-Tenorio, C; Lozano, F; Palacios, Z; Pasquau, J; Ríos, MJ; Samperiz, G; Santos, J; Tornero, C; Verdejo, G | 1 |
| Bicer, C; Brown, K; Crauwels, HM; Osiyemi, O; Zorrilla, C | 1 |
| Baldin, GM; Barbarini, G; Capetti, AF; Cattelan, A; Celesia, BM; Cenderello, G; Cossu, MV; De Socio, GV; Niero, FP; Riccardi, N; Rizzardini, G; Rusconi, S; Soria, A; Sterrantino, G | 1 |
| Dunn, KJ; Kagan, RM; Kaufman, HW; Nettles, RE; Snell, GP | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Rojo, A; Vivancos, MJ; Vizcarra, P | 1 |
| Orkin, C | 1 |
| Akpomiemie, G; Arulappan, N; Boyles, T; Chitauri, G; Hill, A; Maharaj, E; Mashabane, N; Moorhouse, M; Qavi, A; Ripin, D; Serenata, C; Sim, JW; Sinxadi, PZ; Sokhela, S; Stacey, S; Venter, WDF; Wallis, C; Wiesner, L | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Abdullahi, A; Bonnett, L; Defo, VF; Fokam, J; Geretti, AM; Kouanfack, C; Mafotsing Fopoussi, O; Moudourou, S; Torimiro, J | 1 |
| De Clercq, L; De Spiegelaere, W; Rutsaert, S; Vandekerckhove, L | 1 |
| Be, G; Chiesi, S; Lanzafame, M; Lattuada, E; Piacentini, D; Rizzardo, S; Tacconelli, E | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Canestri, A; Costagliola, D; Gallien, S; Potard, V | 1 |
| Bonfanti, P; Carenzi, L; Celesia, BM; Corsi, P; De Socio, G; Di Biagio, A; Franzetti, M; Grosso, C; Guastavigna, M; Madeddu, G; Maggi, P; Martinelli, C; Menzaghi, B; Molteni, C; Orofino, G; Parruti, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Arathoon, E; Baraldi, E; Lavreys, L; Lim, PL; Opravil, M; Schneider, S; Van De Casteele, T | 1 |
| DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y | 1 |
| Benalycherif, A; De Truchis, P; Delassus, JL; Descamps, D; Duvivier, C; Landman, R; Peytavin, G; Tegna, L; Weiss, L; Zucman, D | 1 |
| Cahn, P; Domingo, P; Hodder, S; Lathouwers, E; Opsomer, M; Sension, M; Tomaka, F; Van de Casteele, T | 1 |
| Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Owen, A; Pushpakom, S; Valle, M; Xinarianos, G | 1 |
| Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F | 1 |
| Alfaro, RM; Boyd, SD; Calderon, MM; Chairez, C; Hadigan, C; Kovacs, JA; McManus, M; Nieman, LK; Pau, AK; Penzak, SR | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Montrucchio, C; Trentini, L | 1 |
| Baeten, B; De La Rosa, G; De Meyer, S; Lathouwers, E; Picchio, G; Tomaka, F; Van de Casteele, T | 1 |
| Berhan, A; Berhan, Y | 1 |
| Askeland, G | 1 |
| Daudon, M; de Lastours, V; Ferrari Rafael De Silva, E; Loze, B; Molina, JM; Porcher, R; Sauvageon, H | 1 |
| Berzins, BI; Eron, JJ; Jennings, A; Kim, PS; Kuritzkes, DR; Lederman, MM; Matining, RM; Rinaldo, CR; Taiwo, B; Wilson, CC; Zheng, L | 1 |
| Baran, RW; Caro, JJ; Dietz, B; Migliaccio-Walle, K; Möller, J; Pei, PP; Simpson, KN; Woodward, W | 1 |
| Bridge, DA; Currier, J; Dayaram, YK; Feinberg, J; Mrus, J; Ryan, R; Seyedkazemi, S; Squires, K | 1 |
| Lanzafame, M; Lattuada, E; Rigo, F; Vento, S | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB | 1 |
| Baugh, B; Brown, K; Coate, B; Falcon, R; Kakuda, TN; Mrus, J; Osiyemi, OO; Verboven, P; Wright, R; Yasin, S; Zorrilla, CD | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A | 1 |
| Hevia, H; Ledesma, F; López-Bernaldo, JC; Pedrol, E; Ruiz, S | 1 |
| Blanco, JL; Brunet, M; Calvo, M; Gatell, JM; González, A; Hidalgo, S; Laguno, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A; Pérez, I | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Foisy, MM; Hall, JJ; Houston, S; Hughes, CA; Shafran, S | 1 |
| Guaraldi, G; Santoro, A; Stentarelli, C; Zona, S | 1 |
| Arribas, J; Delft, Yv; Hill, A; Moecklinghoff, C; Pulido, F | 1 |
| Baroncelli, S; Cavalli, A; Cirioni, O; Cusato, M; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Parruti, G; Pirillo, MF; Regazzi, M; Sighinolfi, L; Sozio, F; Tedeschi, S; Villani, P; Vivarelli, A; Volpe, A; Weimer, LE | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Carli, F; Cossarizza, A; Garau, M; Garlassi, E; Guaraldi, G; Lattanzi, A; Nardini, G; Orlando, G; Termini, R; Vernacotola, L; Zona, S | 1 |
| Baran, RW; Desai, K; Dietz, B; Gooch, K; Möller, J; Simpson, K; Van de Steen, O | 1 |
| Benmarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; Lopez-Cortes, LF; Martín-Peña, R; Pérez-Romero, P; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Crespo, M; Curran, A; Guiu, JM; Ribera, E | 1 |
| BenMarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; López-Cortés, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 4 |
| Crespo, M; Curran, A; Domingo, P; Fernández, I; Imaz, A; Iribarren, JA; Knobel, H; Martínez, E; Monteiro, P; Peñaranda, M; Podzamczer, D; Villar, J | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| Afonina, LIu; Voronin, EE | 1 |
| BenMarzouk-Hidalgo, OJ; Gutierrez-Valencia, A; Lluch, A; López-Cortés, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Battegay, M; Elzi, L; Lakatos, B; Marzolini, C; Stoeckle, M | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Castillero-Manzano, M; Escoto-Delgadillo, M; Flores-Soto, M; Gálvez-Gastelum, F; Mata-Munguía, C; Torres-Mendoza, B; Vázquez-Torres, M; Vázquez-Valls, E; Viniegra-Osorio, A | 1 |
| Acosta, EP; Armstrong, WS; Arrendale, RF; Delille, CA; Easley, KA; Lennox, JL; Marconi, VC; Ofotokun, I; Pruett, ST; Sheth, AN; Vunnava, A | 1 |
| Arribas, JR; Pozniak, AL | 1 |
| Antinori, A; Brennan, C; Clotet, B; Dumitru, I; Fehr, J; Feinberg, J; Fujiwara, T; Harris, J; Khuong-Josses, MA; Min, S; Ortiz, R; Pokrovskiy, V; Saag, M; van Lunzen, J | 1 |
| Dupuis, A; Garcia, M; Le Moal, G; Roblot, F; Rochette, N; Venisse, N | 1 |
| Anglaret, X; Danel, C; Eholié, SP; Freedberg, KA; Losina, E; Moh, R; Ouattara, EN; Paltiel, AD; Robine, M; Ross, EL; Walensky, RP; Wong, AY; Yazdanpanah, Y | 1 |
| Abdi, AM; Bonora, S; Calcagno, A; D'Avolio, A; De Nicolò, A; Di Perri, G; Simiele, M | 1 |
| Aouri, M; Arab-Alameddine, M; Buclin, T; Cavassini, M; Csajka, C; Décosterd, LA; Fayet-Mello, A; Gatri, M; Guidi, M; Ledergerber, B; Lubomirov, R; Panchaud, A; Rentsch, K; Rotger, M; Telenti, A; Widmer, N | 1 |
| Asensi, V; Bachiller, P; Blanco, JR; Camacho, A; Castaño, M; Clotet, B; Curto, J; Espinosa, N; Flores, J; Force, L; Gomez-Sirvent, JL; Imaz, A; Iribarren, JA; Knobel, H; López Bernaldo De Quirós, JC; Martín, T; Moreno, V; Ocampo, A; Perez, I; Podzamczer, D; Rojas, J; Rozas, N; Valencia, E; Vergas, J; Viciana, P | 1 |
| Chang, SY; Chen, MY; Cheng, CY; Cheng, SH; Hsieh, SM; Hung, CC; Lin, KY; Sheng, WH; Sun, HY; Tsai, MS; Yang, CJ | 1 |
| Ajassa, C; Ermocida, A; Lichtner, M; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Brochard, P; Dereuddre-Bosquet, N; Desjardins, D; Feyaerts, M; Lagatie, O; Le Grand, R; Malcolm, RK; Murphy, DJ; Perrot, L; Pruvost, A; van Roey, J; Vanhooren, L | 1 |
| Adriaenssen, I; Brogan, AJ; Manuel, SA; Mauskopf, JA; Smets, E | 1 |
| Brochot, A; Hoetelmans, RM; Kakuda, TN; Tomaka, FL; Van De Casteele, T; Vangeneugden, T | 1 |
| Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Mingorance, J; Montes, ML; Pérez-Valero, I; Stella-Ascariz, N; Zamora, FX | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Arnalich, F; Arribas, JR; Bayón, C; Bernardino, JI; Estébanez, M; González-Baeza, A; González-García, JJ; Hernando, A; Lagarde, M; Monge, S; Montes-Ramírez, ML; Pérez-Valero, I; Pulido, F; Zamora, FX | 1 |
| Chokephaibulkit, K; Cressey, TR; Kongstan, N; Lappra, K; Phongsamart, W; Rungmaitree, S; Wittawatmongkol, O | 1 |
| Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Cabrera, A; Domenech, N; Hernández Bel, L; Moratal E Cervera, B | 1 |
| Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P | 1 |
| Imai, Y; Kawamoto, M; Kohara, N; Sekiya, H; Togo, M; Yoshimura, H | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez, MA; Santiuste, C | 1 |
| Burger, D; Colbers, A; Giaquinto, C; Gingelmaier, A; Hawkins, D; Ivanovic, J; Kabeya, K; Moltó, J; Sadiq, ST; Taylor, G; Van der Ende, M; Weizsäcker, K | 1 |
| Bamford, A; Foster, C; James, M; Walters, S; Xiang, N | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Arribas, J; Hill, A; Leeansyah, E; Lewin, SR; Moecklinghoff, C; Solomon, A; Tennakoon, S; Van Delft, Y | 1 |
| Corrêa, JC; D'Arcy, DM; Salgado, HR; Serra, CH | 1 |
| Clotet, B; Curran, A; Di Yacovo, MS; Domingo, P; Ferrer, E; Mateo, MG; Miranda, C; Moltó, J; Podzamczer, D; Santos, JR; Valle, M | 1 |
| Berrio-Galan, D; Bravo, I; Clotet, B; Llibre, JM; Miranda, C; Moltó, J; Paredes, R; Pérez-Alvarez, N; Pérez-Alvarez, S; Santos, JR | 1 |
| Anderson, D; Brinson, C; Cho, M; Coate, B; Kakuda, TN; Ramgopal, M; Ruane, PJ; Ryan, R | 1 |
| Bateson, R; Calvez, V; Ceccherini-Silberstein, F; Clotet, B; Cozzi-Lepri, A; Flandre, P; Grarup, J; Günthard, HF; Hoogstoel, A; Incardona, F; Kaiser, R; Lavreys, L; Ledergerber, B; Lundgren, J; Marcelin, AG; Mercedes Santoro, M; Nelson, M; Nijs, S; Opsomer, M; Paredes, R; Perno, CF; Sonnerborg, A; Tambuyzer, L; Vingerhoets, J | 1 |
| Back, D; Clotet, B; Curran, A; Di Yacovo, MS; Else, L; Ferrer, E; Gisslén, M; Moltó, J; Niubò, J; Podzamczer, D; Tiraboschi, JM; Vila, A; Zetterberg, H | 1 |
| Baccarani, U; Bassetti, M; Bonora, S; Dal Zoppo, S; Della Siega, P; Delle Foglie, P; Giglio, O; Londero, A; Nasta, P; Pea, F; Righi, E; Villa, G | 1 |
| Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C | 1 |
| Baugh, B; de Meyer, S; Gupta, S; Haddad, M; Lathouwers, E; Paquet, A | 1 |
| Minaeva, SV; Moshkovich, GF | 1 |
| Bologna, R; Hendrickx, A; Kakuda, TN; Kumarasamy, N; Lathouwers, E; Opsomer, M; Pilotto, JH; Tomaka, FL; Van de Casteele, T; Violari, A | 1 |
| Charpentier, C; Descamps, D; Fagard, C; Harrigan, PR; Katlama, C; Lee, GQ; Molina, JM; Rodriguez, C; Storto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A | 1 |
| Antinori, A; Biondi, ML; Di Biagio, A; Penco, G; Sterrantino, G; Zaccarelli, M | 1 |
| Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Motta, R; Verucchi, G; Viale, P | 1 |
| Choi, JY; Kee, MK; Kim, SS; Kwon, OK; Oh, HR; Park, M; Rhee, JE | 1 |
| Huhn, GD; Livak, B; Sigman, A | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, R; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Ferenci, T; Gerlei, Z; Horváth, G; Kormos, L; Makara, M; Rupnik, Z; Sulyok, M; Szlávik, J; Újhelyi, E; Vályi-Nagy, I | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Best, BM; Burchett, SK; Capparelli, EV; Cressey, TR; Kreitchmann, R; Mirochnick, M; Mofenson, LM; Rungruengthanakit, K; Shapiro, D; Smith, E; Stek, A; Wang, J | 1 |
| Crauwels, H; de Smedt, G; Iterbeke, K; Kakuda, TN; Opsomer, M; Tomaka, F; van de Casteele, T; Vanveggel, S | 1 |
| Ahmed, N; Ainsworth, J; Okoli, C | 1 |
| Arends, JE; Boateng, CP; Buijs, BS; Hoepelman, AI; van den Berk, GE; van Maarseveen, EM | 1 |
| Bartakke, US; Bhalekar, MR; Dube, A; Kshirsagar, SJ; Madgulkar, AR; Upadhaya, PG | 1 |
| Walter, M | 1 |
| Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT | 1 |
| Fairlie, L; Kindra, G; Moultrie, H; Sipambo, N | 1 |
| Raines, RT; Windsor, IW | 1 |
| Burgos, J; Crespo, M; Curran, A; Falcó, V; López, RM; Martí, R; Melià, MJ; Navarro, J; Ocaña, I; Pérez, M; Ribera, E | 1 |
| Gauthier, TP; Schafer, JJ; Sherman, EM; Unger, NR; Worley, MV | 1 |
| Keating, GM | 1 |
| Bellistrì, GM; Cannizzo, ES; d'Arminio Monforte, A; Garau, M; Mancusi, D; Marchetti, G; Savoldi, A; Termini, R; Tincati, C | 1 |
| Burger, D; Colbers, A; Greupink, R; Litjens, C; Russel, FG | 1 |
| Brennan, C; Cavassini, M; Clotet, B; de Oliveira, CF; Givens, N; Henry, K; Kulagin, V; Lazzarin, A; Molina, JM; van Lunzen, J | 1 |
| Blanes, M; Calabuig, E; Cuellar, S; Di Benedetto, N; Lacruz, J; López, J; Montero-Alonso, M; Salavert, M | 1 |
| Burling, K; Cason, J; Fox, J; Hamzah, L; Ibrahim, F; Iveson, H; Jendrulek, I; Kulasegaram, R; Mant, C; Post, FA; Taylor, C; Teague, A; Tiraboschi, JM; Toby, M; Wandolo, E | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| Hung, CC; Lin, KY | 1 |
| Avihingsanon, A; Do, T; Putcharoen, O; Ruxrungtham, K | 1 |
| Aoki, M; Aoki-Ogata, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nakamura, T; Nakata, H; Takamatsu, Y; Yamagata, Y; Yedidi, RS | 1 |
| Capetti, A; Cossu, MV; Rizzardini, G | 1 |
| Fulco, PP; Gomes, D; Nixon, D; Smith, K | 1 |
| Brouillette, M; Farr, AM; Johnston, SS; Ritchings, C; Rosenblatt, L | 1 |
| Bloch, M; Carr, A; Lee, FJ; Mackenzie, N; Marriott, D; Richardson, R | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Bon, I; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Re, MC; Viale, P | 1 |
| Fox, J; Hamzah, L; Kulasegaram, R; Post, F; Siddiqui, A; Tiraboschi, J | 1 |
| Belkhir, L; Capron, A; De Laveleye, M; Delongie, KA; Elens, L; Haufroid, V; Vandercam, B; Vincent, A; Yombi, J; Zech, F | 1 |
| Bravo, I; Cañadas, MP; Clotet, B; García-Rosado, D; Llibre, JM; Moltó, J; Paredes, R; Pérez-Álvarez, N; Santos, JR | 1 |
| Brockmeyer, NH; Castagna, A; Churchill, D; Cozzi-Lepri, A; De Luca, A; De Wit, S; Descamps, D; Dunn, D; Flandre, P; Garcia, F; Günthard, HF; Imaz, A; Kordossis, T; Mussini, C; Obel, N; Perno, CF; Reiss, P; Roca, B; Santoro, MM; Schülter, E; Torti, C; van Sighem, A; Wensing, A; Wittkop, L; Zangerle, R; Zazzi, M | 1 |
| Callegaro, A; Di Filippo, E; Maggiolo, F; Serna Ortega, PA; Valenti, D | 1 |
| Baugh, BP; Coate, B; Dayaram, YK; De La Rosa, G; Overton, ET; Perniciaro, A; Ryan, R; Tebas, P | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Fletcher, CV; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Wiznia, A; Yogev, R | 1 |
| Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S | 1 |
| Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Foca, M; Graham, B; Hazra, R; Jean-Philippe, P; King, J; Wiznia, A; Yogev, R | 1 |
| Baugh, B; Brown, K; Crauwels, HM; Hillewaert, V; Kakuda, TN; Osiyemi, OO; Ryan, B; Verboven, P; Yasin, S; Zorrilla, C | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Larson, KB; Wiznia, A; Yogev, R | 1 |
| Fox, J; Hamzah, L; Jendruleck, I; Kulasegaram, R; Murray, T; Post, F; Teague, A; Tiraboschi, J | 1 |
| Castro-Iglesias, Á; Cid, P; Grandal, M; Margusino, L; Mena, Á; Pedreira, JD; Pernas, B; Pértega, S; Poveda, E; Tabernilla, A | 1 |
| Airoldi, G; Antinori, A; Bini, T; Castagna, A; Colella, E; Gianotti, N; Mancusi, D; Meraviglia, P; Monforte, Ad; Mussini, C; Rusconi, S; Termini, R | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Alteri, C; Andreoni, M; Antinori, A; Armenia, D; Bertoli, A; Borghi, V; Ceccherini-Silberstein, F; Cicalini, S; D'Offizi, G; Di Carlo, D; Forbici, F; Giuliani, M; Gori, C; Maffongelli, G; Mussini, C; Nicastri, E; Perno, CF; Pinnetti, C; Santoro, MM; Zaccarelli, M | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Heatley, MK; Roberts, B; Yoganathan, K | 1 |
| Castilla, JA; Gonzalvo, MC; Hidalgo-Tenorio, C; Javier, R; Lopez-Ruz, MA; López-Zúñiga, MA; Navas, P; Pasquau, J; Sampedro, A | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Baldelli, F; Celesia, BM; Focà, E; Galli, L; Gianotti, N; Lazzarin, A; Lo Caputo, S; Maserati, R; Palvarini, L; Ripamonti, D; Sighinolfi, L; Sterrantino, G | 1 |
| Carpio, F; DeJesus, E; Fusco, G; Fusco, J; Henegar, C; Hsu, R; Lackey, P; Mills, A; Pierone, G; Wohlfeiler, M | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Baldin, GM; Capetti, AF; Cattelan, AM; Cenderello, G; Cima, S; Cossu, MV; De Socio, GV; Niero, FP; Riccardi, N; Rizzardini, G; Rusconi, S; Sasset, L; Sterrantino, G | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Chávez-García, M; Domínguez-Hermosillo, JC; García-Gámez, JG; Gaytán-Martínez, JE; Herrera-González, NE; Huerta-García, G; Jiménez-Romero, A; Mata-Marin, JA; Nuñez-Rodríguez, N | 1 |
| Belkhir, L; Elens, L; Haufroid, V; Panin, N; Vandercam, B; Vincent, A; Yombi, JC; Zech, F | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Post, FA | 1 |
| Dunn, DT; El Bouzidi, K; Mackie, N; Mbisa, JL; Phillips, AN; Pillay, D; Pozniak, AL; Sabin, CA; Tostevin, A; White, E | 1 |
| Asensi-Díez, R; Castaño-Carracedo, MA; Del Rio-Valencia, JC; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Claiborne, DT; Collier, DA; Deymier, MJ; Goldstein, RA; Gupta, RK; Hunter, E; Prince, JL; Sutherland, KA | 1 |
| Benmarzouk-Hidalgo, OJ; Espinosa, N; Fernandez-Magdaleno, T; Gutierrez-Valencia, A; Llaves, S; Lopez-Cortes, LF; Viciana, P | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Kaleebu, P; Kapaata, AA; Kasamba, I; Kazooba, P; Lutaakome, J; Lyagoba, F; Mayanja, BN; Munderi, P; Namakoola, I | 1 |
| Blanco, JR | 1 |
| Bisbal, O; de Lagarde, M; Domínguez, L; Matarranz, M; Rubio, R | 1 |
| Blanco Arévalo, JL | 1 |
| González-Domenech, CM; Palacios, R; Santos, J | 1 |
| Iribarren, JA | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| Khoo, S; Owen, A; Roberts, O; Siccardi, M | 1 |
| Audelin, AM; Jørgensen, LB; Lebech, AM; Petersen, AB | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Andrade-Villanueva, J; De Meyer, S; De Pauw, M; Dejesus, E; Fourie, J; Khanlou, H; Lefebvre, E; Ortiz, R; Spinosa-Guzman, S; van Lunzen, J; Vangeneugden, T; Voronin, E | 1 |
| Blanche, S; de Truchis, P; Delaugerre, C; Dominguez, S; Ghosn, J; Molina, JM; Mortier, E; Palmer, P; Pavie, J; Roudiere, L | 1 |
| Cedeño, S; Clotet, B; Else, L; Khoo, S; Llibre, JM; Miranda, C; Moltó, J; Pérez-Alvarez, N; Santos, JR; Valle, M | 1 |
| Brunet, C; Calvez, V; Canestri, A; Flandre, P; Katlama, C; Lambert-Niclot, S; Malet, I; Marcelin, AG; Soulié, C; Tubiana, R; Wirden, M | 1 |
| de Béthune, MP; De Meyer, SM; Miralles, GD; Spinosa-Guzman, S; Vangeneugden, TJ | 1 |
| Hoy, J; Rotty, J | 1 |
| DeJesus, E; Gathe, JC; Gottlieb, MS; Greenberg, ML; Guittari, CJ; Zolopa, AR | 1 |
| Rawizza, HE; Sax, PE | 1 |
| Cerini, C; Fasan, S; Giacomet, V; Marchetti, G; Meroni, L; Pradella, A; Vanzulli, A; Viganò, A; Zuccotti, GV | 1 |
| Beatty, G; de Béthune, MP; Hill, A; Lefebvre, E; Opravil, M; Pozniak, A | 1 |
| Cartledge, JD; Lascar, M | 1 |
| Barrail-Tran, A; Chaix, ML; Delfraissy, JF; Ghosn, J; Pallier, C; Sahali, S | 1 |
| Kuhlmann, B | 1 |
| Vallone, A; Vento, S | 1 |
| Abusamra, L; Cahn, P; Cesar, C; Fink, V; Gun, A; Krolewiecki, A; Lattner, J; Patterson, P; Sued, O | 1 |
| Harada, Y; Iwata, M; Yoshida, S | 1 |
| Castagna, A; Fusetti, G; Galli, L; Gianotti, N; Lazzarin, A; Salpietro, S; Seminari, E; Spagnuolo, V | 1 |
| Brun-Vézinet, F; Calvez, V; Descamps, D; Felices, M; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Roquebert, B; Yeni, P | 1 |
| Acosta, EP; King, JR; Long, MC | 1 |
| Capetti, AF; Landonio, S; Perno, CF; Piconi, S; Rizzardini, G | 1 |
| Clotet, B | 2 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Estrada, V; Fuster, M | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Arazo Garcés, P; Omiste Sanvicente, T | 1 |
| Camacho, A; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J | 1 |
| Antela López, A | 1 |
| García Deltoro, M | 1 |
| Clotet, B; Moltó, J; Valle, M | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; DeMasi, R; Hill, A; Picchio, G | 1 |
| Cattaneo, D; Cortinovis, M; Maggiolo, F; Ripamonti, D; Suter, F | 1 |
| Sax, PE | 4 |
| De Meulder, M; Gisslén, M; Izadkhashti, A; Mallon, PW; Price, RW; Timmerman, P; Yilmaz, A | 1 |
| Keam, SJ; McKeage, K; Perry, CM | 1 |
| Battegay, M; Marzolini, C; Mayr, M; Mertz, D | 1 |
| Bernardini, C; Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Secondo, G; Viscoli, C | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LX | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; Dierynck, I; Lathouwers, E; Lefebvre, E; Picchio, G; Spinosa-Guzman, S; Van Baelen, B; Vangeneugden, T | 1 |
| Dailly, E; Deslandes, G; Jolliet, P; Martin, J; Perré, P; Raffi, F | 1 |
| Abeele, CV; Cassetti, I; Dierynck, I; Girard, PM; Jayaweera, D; Lavreys, L; Mills, AM; Nelson, M; Ruxrungtham, K; Sekar, V; Workman, C | 1 |
| DeLaitsch, LL; Genz, M; Klaskala, W; Lin, HY; McFarland, G; McKinnell, JA; Mrus, JM; Mugavero, MJ; Nevin, CN; Raper, JL; Saag, MS; Willig, JH | 1 |
| Barreiro, P; Fernández-Montero, JV; Soriano, V | 1 |
| Arribas, JR | 2 |
| Calvez, V; Hill, A; Marcelin, AG | 1 |
| Arenas Villarroel, LJ; Gavilán Montenegro, MJ; Marcos Bravo, MC; Martínez Vázquez, C; Martínez Vilela, J; Miralles Alvarez, C; Ocampo Hermida, A; Pérez Rodríguez, MT; Rodríguez Dasilva, A | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T | 1 |
| Bollens, D; Castaigne, V; Girard, PM; Meyohas, MC; Morand-Joubert, L; Pacanowski, J; Poirier, JM | 1 |
| Blanche, S; Bologna, R; Cahn, P; Dierynck, I; Flynn, P; Fortuny, C; Rugina, S; Sekar, V; Spinosa-Guzman, S; van Baelen, B; Vis, P | 1 |
| Azu, MC; Pahk, R; Sandoval, S; Taira, BR | 1 |
| Arastéh, K; De Meyer, S; Grinsztejn, B; Hoy, J; Jayaweera, D; Pozniak, A; Roberts, A; Tomaka, F; Vangeneugden, T; Yeni, P | 1 |
| Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Aumaître, H; Blanche, S; Chaix, ML; Firtion, G; Frange, P; Rabaud, C; Reliquet, V; Tamalet, C; Thuret, I; Tricoire, J | 1 |
| Aiuti, F; Esposito, A; Fantauzzi, A; Isgro, A; Leti, W; Mezzaroma, I; Pastori, D | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LA | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Arribas, JR; Clumeck, N; Fätkenheuer, G; Gerstoft, J; Hill, A; Horban, A; Moecklinghoff, C; Nelson, M; Pulido, F; Stark, T; van Delft, Y | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Aegerter, P; Blanche, S; Buyck, JF; Chaix, ML; de Truchis, P; Delaugerre, C; Force, G; Mortier, E; Peytavin, G; Rouveix, E; Viard, JP; Zucman, D | 1 |
| Portilla, J | 1 |
| Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M | 1 |
| Berger, DS; Cheng, AK; Chuck, SL; Enejosa, JV; Kearney, BP; Lampiris, H; Zhong, L; Zolopa, AR | 1 |
| De Luca, A; Navarra, P; Pinnetti, C; Ragazzoni, E; Tamburrini, E | 1 |
| de Souza, DF; Diaz, RS; Inocencio, LA; Janini, LM; Munerato, P; Oliveros, MP; Pereira, AA; Sucupira, MC | 1 |
| McKeage, K; Scott, LJ | 1 |
| Briz, V; de José, MI; González-Tomé, MI; León Leal, JA; Muñoz-Fernández, MA; Navarro, ML; Palladino, C; Ramos, JT | 1 |
| Hull, MW; Montaner, JS | 1 |
| Baril, JG; Brenner, B; Cantin, R; Charest, H; Grant, P; Liu, TF; Roger, M; Shafer, R; Talbot, A; Taylor, J; Zolopa, A | 1 |
| De Paepe, E; De Pauw, M; Hoetelmans, RM; Sekar, V; Spinosa-Guzman, S; Stevens, T; Tomaka, F | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Barbanoj, MJ; Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Mothe, B; Negredo, E; Santos, JR; Valle, M; Videla, S; Yritia, M | 1 |
| Bellagamba, R; Ivanovic, J; Mazzitelli, L; Narciso, P; Nicastri, E; Signore, F; Tempestilli, M; Tommasi, C; Vallone, C | 1 |
| Anta, L; Blanco, JL; Casado, JL; de Mendoza, C; García, F; Gómez-Sirvent, JL; Gutiérrez, F; Iribarren, JA; Poveda, E; Soriano, V | 1 |
| Chen, L; Demasi, R; Girard, PM; Lavreys, L; Nelson, M; Sekar, V; Smets, E | 1 |
| Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 2 |
| Fujii, T; Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Miyazaki, N; Nakamura, H; Odawara, T | 1 |
| Antoniou, T; Bitnun, A; Brophy, J; Jaworsky, D; Loutfy, MR; Samson, L; Thompson, C; Yudin, MH | 1 |
| Berckmans, C; De Pauw, M; Hoetelmans, R; Lavreys, L; Sekar, V; Spinosa-Guzman, S; Van de Casteele, T; Vangeneugden, T | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Crespo, M; Curran, A; Deig, E; Domingo, P; Gutirerrez, M; Imaz, A; Lopez, RM; Mateo, G; Ocaña, I; Ribera, E | 1 |
| Algarte-Genin, M; Calvez, V; Duvivier, C; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Molina, JM; Pakianather, S; Peytavin, G; Poirot, C; Valantin, MA | 1 |
| Back, DJ; Berry, A; Dufty, NE; Else, L; Gilleran, G; Jayasuriya, AN; Smit, EJ; Taylor, S | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Algarte-Genin, M; Duvivier, C; Flandre, P; Girard, PM; Hoen, B; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Molina, JM; Pakianather, S; Peytavin, G; Valantin, MA | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Baldridge, A; Ghosh, AK; Miguel, SG; Mitsuya, H; Rao, KV; Wang, YF; Weber, IT; Xu, CX | 1 |
| Azijn, H; Daems, B; de Béthune, MP; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| Battegay, M; Bernasconi, E; Böni, J; Bucher, HC; Cavassini, M; Fux, CA; Günthard, HF; Hirschel, B; Opravil, M; Rickenbach, M; Scherrer, AU; Vernazza, P; Yerly, S; Young, J | 1 |
| Barrail-Tran, A; Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Goldwirt, L; Katlama, C; Molina, JM; Piketty, C; Taburet, AM; Yazdanpanah, Y | 1 |
| Aban, I; De La Rosa, GR; Delaitsch, LL; McKinnel, JA; Mrus, JM; Mugavero, MJ; Nevin, CR; Raper, JL; Saag, MS; Willig, JH; Ye, J | 1 |
| Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG | 1 |
| Baietto, L; Bonora, S; Calcagno, A; Cometto, C; D'Avolio, A; Di Perri, G; Ferramosca, S; Galli, M; Ghisetti, V; Gonzalez de Requena, D; Magnani, S; Rusconi, S; Viganò, O; Vitiello, P | 1 |
| Clotet, B; Grinsztejn, B; Haubrich, R; Katlama, C; Mills, A; Molina, JM; Nijs, S; Towner, W; Trottier, B; Vingerhoets, J; Witek, J; Woodfall, B | 1 |
| Barbanoj, MJ; Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Negredo, E; Valle, M | 1 |
| Alas, B; Perniciaro, A; Ruane, P; Ryan, R; Witek, J | 1 |
| Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S | 1 |
| Parienti, JJ | 1 |
| Allsop, JM; Garvey, L; Higgs, C; Hill, A; Mohammed, P; Nelson, M; Taylor-Robinson, SD; Winston, A | 1 |
| Bracciale, L; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Parruti, G; Prosperi, M; Ragazzoni, E | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Arribas, JR; Pérez-Valero, I | 1 |
| Falcon, R; Jennings, S; Kashuba, A; Mrus, J; Patterson, K | 1 |
| Annemans, L; Hill, AM; Mauskopf, J; Smets, E | 1 |
| Bellos, N; Clotet, B; Hill, AM; Johnson, M; Smets, E; Stoll, M | 1 |
| Brogan, A; Martin, S; Mauskopf, J; Smets, E | 1 |
| Allegri, G; Annemans, L; Caekelbergh, K; Hemmet, L; Löthgren, M; Moeremans, K; Smets, E; Wyffels, V | 1 |
| Brogan, A; Mauskopf, J; Smets, E; Talbird, SE | 1 |
| Allegri, G; Hemmett, L; Hjelmgren, J; Moeremans, K; Smets, E | 1 |
| Allegri, G; Gebo, K; Hemmett, L; Hill, AM; Löthgren, M; Smets, E | 1 |
| Colin, X; Costagliola, D; Guillon, P; Lafuma, A; Mauskopf, J; Smets, E | 1 |
| Cahn, P; Clumeck, N; Mills, A; Molina, JM; Nijs, S; Vingerhoets, J; Witek, J | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Cahn, P; De Doncker, P; Fourie, J; Grinsztejn, B; Hodder, S; Lathouwers, E; Molina, JM; Ruxrungtham, K; Tomaka, F; Van De Casteele, T; Workman, C | 1 |
| De La Rosa, G; Fullerton, DS; Mrus, JM; Smets, E | 1 |
| Aboh, S; Bosivert, N; Duke, N | 1 |
| Cattaneo, D; Gervasoni, C | 1 |
| Allavena, C; Billaud, E; Bouquié, R; Dailly, E; Deslandes, G; Ferré, V; Garnier, E; Jolliet, P; Raffi, F; Reliquet, V; Rodallec, A | 1 |
| Aboulker, JP; Barrail-Tran, A; Braun, J; Charreau, I; de Castro, N; Delaugerre, C; Goldwirt, L; Lascoux-Combe, C; Molina, JM; Raffi, F; Taburet, AM | 1 |
| Álvarez-Tejado, M; Clotet, B; Codoñer, FM; Dalmau, D; Delgado, R; García, F; Paredes, R; Pou, C; Ruiz, L; Thielen, A | 1 |
| Currier, JS; De La Rosa, G; Martorell, C; Mrus, J; Osiyemi, O; Ryan, R; Yin, MT | 1 |
| Arribas, J; Banhegyi, D; Clumeck, N; Hill, A; Moecklinghoff, C; Rieger, A; Schmidt, W; Van Delft, Y | 1 |
| Corti, N; Kovari, H; Kullak-Ublick, GA; Müller, V; Taegtmeyer, AB | 1 |
| Antinori, A; Baldanti, F; De Luca, A; Di Giambenedetto, S; Di Perri, G; Gianotti, N; Maserati, R; Micheli, V; Narciso, P; Perno, CF; Prosperi, MC; Santoro, MM; Zazzi, M | 1 |
| Phung, BC; Yeni, P | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Brun-Vézinet, F; Calvez, V; Charpentier, C; Descamps, D; Felices, M; Katlama, C; Lambert-Niclot, S; Landman, R; Larrouy, L; Marcelin, AG; Peytavin, G; Valantin, MA; Yeni, P | 1 |
| Acosta, EP; Bastow, B; Berzins, BI; Eron, JJ; Gallien, S; Kim, PS; Kuritzkes, DR; Matining, RM; Taiwo, B; Wilson, CC; Zheng, L | 1 |
| Dierynck, I; Jonckers, TH; Kraus, G; Nalam, MN; Picchio, G; Raoof, A; Schiffer, CA; Van Ginderen, M; Van Marck, H | 1 |
| Back, NK; Blom, P; Burger, DM; Cornelissen, M; Portegies, P; Prins, JM; van der Valk, M | 1 |
| Algarte-Genin, M; Calvez, V; Duvivier, C; Flandre, P; Girard, PM; Haim-Boukobza, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Valantin, MA; Yazdanpanah, Y | 1 |
| Abbas, R; Back, D; Boffito, M; Egan, D; Gazzard, B; Gedela, K; Higgs, C; Jackson, A; Khoo, S; Liptrott, N; Watson, V | 1 |
| Baldelli, S; Boreggio, G; Cattaneo, D; Clementi, E; Cozzi, V; Fucile, S; Gervasoni, C; Landonio, S; Meraviglia, P; Rizzardini, G | 1 |
| Elgadi, MM; Piliero, PJ | 1 |
| Bonora, S; Borghi, V; Corsi, P; De Luca, A; Leoncini, F; Meraviglia, P; Sterrantino, G; Trotta, M; Zaccarelli, M; Zazzi, M | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A | 1 |
| Ajana, F; Cabiè, A; Curjol, A; Cuzin, L; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Morand-Joubert, L; Ponscarme, D; Schneider, L; Slama, L; Taburet, AM; Valantin, MA | 1 |
| Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J | 1 |
| Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Teruya, K; Tsukada, K | 1 |
| Baldanti, F; Carli, T; Colao, G; Di Giambenedetto, S; Maggiolo, F; Sterrantino, G; Zaccarelli, M; Zazzi, M | 1 |
| Abongomera, G; Back, D; Boffito, M; Dickinson, L; Gazzard, B; Gedela, K; Jackson, A; Khoo, S; Moyle, G; Taylor, J | 1 |
| Anceau, A; Gostkorzewicz, J; Hill, A; Ledesma, F; Moecklinghoff, C; Pasquau, J | 1 |
| Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P | 1 |
| Donegan, KL; Dunn, D; Gibb, DM; Judd, A; Lyall, H; Menson, E; Pillay, D; Tudor-Williams, G; Walker, AS | 1 |
| Balakrishnan, P; Kantor, R; Katzenstein, D; Kumarasamy, N; Mayer, KH; Rifkin, S; Saravanan, S; Sivamalar, S; Solomon, S; Solomon, SS; Vidya, M; Yeptomi, T | 1 |
| Bánhegyi, D; da Cunha, CA; De Meyer, S; Katlama, C; Rachlis, A; Schneider, S; Tomaka, F; Van De Casteele, T; Vandevoorde, A; Workman, C | 1 |
| Algarte-Genin, M; Calvez, V; Delaugerre, C; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Morand-Joubert, L; Peytavin, G; Sayon, S; Valantin, MA | 1 |
| Algarte Genin, M; Cuzin, L; de Kerviler, E; Flandre, P; Inaoui, R; Katlama, C; Kolta, S; Meynard, JL; Ponscarme, D; Slama, L; Valantin, MA | 1 |
| Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Negredo, E; Valle, M | 1 |
| Arribas, J; Hill, A; Moecklinghoff, C; van Delft, Y; Xi, N | 1 |
| Oka, S | 1 |
| Capparelli, EV; Neely, MN; Rakhmanina, NY | 1 |
| Bertucci, R; Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Marinaro, L; Siccardi, M; Simiele, M; Yilmaz, A | 1 |
| Hill, A; Moecklinghoff, C; Winston, A | 1 |
| Feinberg, J; Robertson, J | 1 |
| Bravo, I; Clotet, B; Llibre, JM; Moltó, J; Negredo, E; Ornelas, A; Paredes, R; Santos, JR | 1 |
| Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Zetterberg, H | 1 |
| D'Arcy, DM; dos Reis Serra, CH; Nunes Salgado, HR; Ruela Corrêa, JC | 1 |
| Bocket, L; Calvez, V; Dos Santos, G; Flandre, P; Fourati, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Pakianather, S; Sayon, S; Soulie, C; Valantin, MA; Wirden, M | 1 |
| Ananworanich, J; Burger, D; Chokephaibulkit, K; Gorowara, M; Kerr, SJ; Pasomsap, C; Phongsamart, W; Prasitsuebsai, W; Puthanakit, T; Sekar, V; Sophonphan, J; Suwanlerk, T; Vanprapar, N; Wittawatmongkol, O | 1 |
| Calza, L; Manfredi, R | 1 |
| Chermak, A; Courbon, E; Duvivier, C; Flandre, P; Fourn, E; Ghosn, J; Houssaini, A; Katlama, C; Lambert-Niclot, S; Murphy, R; Peytavin, G; Schneider, L; Simon, A; Slama, L | 1 |
| Balakrishnan, P; Kantor, R; Kumarasamy, N; Madhavan, V; Poongulali, S; Saravanan, S; Schooley, RT; Sivamalar, S; Smith, DM; Solomon, S; Solomon, SS | 1 |
| DeJesus, E; Khanlou, H; Lathouwers, E; Lefebvre, E; Opsomer, M; Orkin, C; Stoehr, A; Supparatpinyo, K; Tomaka, F; Van de Casteele, T | 1 |
| Liedtke, MD; Rathbun, RC; Vanguri, A | 1 |
| Best, BM; Capparelli, E; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; Marra, CM; McArthur, J; McCutchan, JA; Morgello, S; Rossi, SS; Simpson, DM | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Ambrosioni, J; Assouline, B; Calmy, A; Daali, Y; Desmeules, J; Fathi, M; I Lorenzini, K; Rebsamen, M; Samer, CF | 1 |
| Flexner, C; Lee, LS; Pham, P | 1 |
| Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Taburet, AM; Visseaux, B; Yazdanpanah, Y | 1 |
| Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A | 1 |
| Arastéh, K; Clumeck, N; De Meyer, S; Lazzarin, A; Lefebvre, E; Muller, H; Peeters, M; Pozniak, A; Rinehart, A | 1 |
| Susman, E | 1 |
| Feinberg, J | 1 |
| Arastéh, K; Müller, M | 1 |
| Tachikawa, N | 1 |
| Dauer, B | 1 |
| Hicks, CB | 1 |
| Boyle, BA | 1 |
| Alcolea, A; Blanco, F; Briz, V; García-Gascó, P; Poveda, E; Soriano, V | 1 |
| Boffito, M; Mallon, PW; Winston, A | 1 |
| Bernard, AJ; Boffito, M; Churchill, D; Edwards, S; Fisher, N; Gazzard, B; Geretti, AM; Johnson, M; Leen, C; Peters, B; Pozniak, A; Ross, J; Walsh, J; Wilkins, E; Youle, M | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Temesgen, Z | 1 |
| de Béthune, MP; Hertogs, K | 1 |
| Esposito, R; Gatell, JM; Goffard, JC; Grinsztejn, B; Katlama, C; Parys, W; Pozniak, A; Rockstroh, J; Stoehr, A; Vangeneugden, T; Vetter, N; Yeni, P | 1 |
| Edmunds-Ogbuokiri, T | 1 |
| MacArthur, RD | 1 |
| Bellos, N; Clotet, B; Cohen, C; Cooper, D; Farthing, C; Goffard, JC; Haubrich, R; Jayaweera, D; Katlama, C; Lazzarin, A; Lefebvre, E; Markowitz, M; Molina, JM; Ruane, P; Spinosa-Guzman, S; Wilkin, T; Wöhrmann, A | 1 |
| Hill, A; Montaner, J; Smith, C | 1 |
| Hill, A; Moyle, G | 1 |
| Gallant, JE; Hoffman, CJ | 1 |
| Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G | 1 |
| Bernard, EJ | 1 |
| Boffito, M; Fletcher, C; Gazzard, B; Hoetelmans, R; Jackson, A; Miralles, D; Moyle, G; Nelson, M; Pozniak, A; Tolowinska, I; Winston, A | 1 |
| Hirschel, B; Perneger, T | 1 |
| Banhegyi, D; Berger, D; de Béthune, MP; De Pauw, M; Lefebvre, E; Madruga, JV; McMurchie, M; Norris, D; Ruxrungtham, K; Spinosa-Guzman, S; Suter, F; Tomaka, F; Vangeneugden, T | 1 |
| Cohen, C; Grinsztejn, B; Katlama, C; Lefebvre, E; Meyer, SD; Miralles, D; Molina, JM; Parys, W; Pedro, Rde J; Timerman, A; Vangeneugden, T | 1 |
| Maeda, K; Mitsuya, H | 1 |
| Colebunders, R; De Roo, A; Gheuens, E; Hollanders, E; Maniewski, U; Schepens, T; Vlieghe, E | 1 |
| Briz, V; Corral, A; de Mendoza, C; González-Lahoz, J; Martin-Carbonero, L; Poveda, E; Soriano, V | 1 |
| Busse, KH; Penzak, SR | 1 |
| Hill, A; Molina, JM | 1 |
| Gebo, K; Hill, A | 1 |
| de Mendoza, C; Pattery, T; Poveda, E; Soriano, V; Villacian, J; Vispo, E | 1 |
| Banno, K; Hirano, A; Kaneda, T; Kudaka, Y; Okumura, N; Takahashi, M | 1 |
| McCoy, C | 1 |
| Hall, D | 1 |
| Haubrich, R | 1 |
| Fessel, WJ; Liu, TF; Mitsuya, Y; Rhee, SY; Shafer, RW | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Lorena, B; Sciandra, M; Siccardi, M; Trentini, L | 1 |
| El-Atrouni, WI; Temesgen, Z | 1 |
| Hou, T; McLaughlin, WA; Wang, W | 1 |
| Agher, R; Blanc, C; Calvez, V; Canestri, A; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Soulié, C; Wirden, M | 1 |
| Fenton, C; Perry, CM | 1 |
| Holodniy, M | 1 |
| Sherer, R | 1 |
| de Béthune, MP; De Meyer, S; Picchio, G | 1 |
| Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C | 1 |
| Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R | 1 |
| Andres, DA; Coffinier, C; Farber, EA; Fong, LG; Hrycyna, CA; Hudon, SE; Lee, R; Miner, JH; Nobumori, C; Spielmann, HP; Young, SG | 1 |
| Gathe, J | 1 |
| Choe, S; Corral, A; de Mendoza, C; García-Gasco, P; Parkin, N; Poveda, E; Soriano, V | 1 |
| de Béthune, MP; de Meyer, S; de Paepe, E; Lefebvre, E; Picchio, G; van Baelen, B; van Marck, H; Vangeneugden, T | 1 |
| Back, D; Hoetelmans, RM; Sekar, V | 1 |
| Taéron, C | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T | 1 |
| Bollens, D; Bonarek, M; Breilh, D; Fleury, H; Girard, PM; Joubert, LM; Neau, D; Pellegrin, I; Pellegrin, JL; Saux, MC; Thiébaut, R; Winters, B; Wittkop, L | 1 |
82 review(s) available for darunavir and HIV Coinfection
| Article | Year |
|---|---|
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides | 2007 |
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides | 2009 |
Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Ritonavir; Tenofovir | 2023 |
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Topics: Adenine; Adolescent; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Pharmaceutical Preparations; Raltegravir Potassium; Tenofovir; Young Adult | 2023 |
Darunavir: A comprehensive profile.
Topics: Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pregnancy; United States | 2021 |
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic | 2021 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Darunavir for use in pregnant women with HIV.
Topics: Animals; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious | 2017 |
Contemporary protease inhibitors and cardiovascular risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir | 2018 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2018 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Development of darunavir over the entire spectrum of HIV infection.
Topics: Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans | 2018 |
Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV-1; Humans; Odds Ratio; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
HIV-associated lipodystrophy: impact of antiretroviral therapy.
Topics: Adiposity; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Nucleosides; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides | 2013 |
Darunavir: a review of its use in the management of HIV-1 infection.
Topics: Darunavir; Health Care Costs; HIV Infections; HIV-1; Humans; Sulfonamides | 2014 |
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
[Use of darunavir in HIV-infected women during pregnancy].
Topics: Darunavir; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy; Pregnancy Complications, Infectious; Sulfonamides; Treatment Outcome | 2013 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Topics: Age Factors; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Pregnancy; Sex Factors; Sulfonamides | 2014 |
A critical review of properties of darunavir and analytical methods for its determination.
Topics: Darunavir; Drug Delivery Systems; HIV Infections; HIV Protease Inhibitors; Humans; Quality Control; Sulfonamides | 2014 |
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome | 2015 |
Darunavir/cobicistat once daily for the treatment of HIV.
Topics: Clinical Trials as Topic; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Treatment Outcome | 2015 |
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Quinolones | 2015 |
Darunavir: A Review in Pediatric HIV-1 Infection.
Topics: Anti-Retroviral Agents; Child; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans | 2015 |
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Topics: Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Combinations; Drug Interactions; Food-Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Risk Factors; Treatment Outcome | 2015 |
Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.
Topics: Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans | 2015 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
[Rescue therapy with darunavir for treatment-experienced HIV-infected patients].
Topics: Clinical Trials as Topic; Darunavir; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Treatment Outcome; Viral Load | 2016 |
[Long-term safety and effectiveness of darunavir].
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Treatment Outcome | 2016 |
[Darunavir as initial therapy for human immunodeficiency virus infection and as a strategy for switching regimen not motivated by virological failure].
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; HIV Infections; Humans; Ritonavir; Viral Load | 2016 |
[Pharmacological aspects of darunavir/cobicistat].
Topics: Cobicistat; Darunavir; Drug Combinations; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.
Topics: Animals; Clinical Competence; Clinical Trials as Topic; Darunavir; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Practice Patterns, Physicians'; Sulfonamides; Viral Load | 2008 |
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Treatment Outcome | 2008 |
[Pharmacological and clinical profile of Darnavir (Prezista)].
Topics: Clinical Trials, Phase III as Topic; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides | 2008 |
Pharmacologic aspects of new antiretroviral drugs.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Nitriles; Organophosphonates; Oxazines; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides | 2009 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia | 2008 |
[Darunavir in HIV/HVC/HVB coinfection].
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Inactivation, Metabolic; Liver; Liver Cirrhosis; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
[Safety and tolerability of darunavir].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lopinavir; Male; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
[Pharmacological interactions with darunavir].
Topics: Anti-HIV Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cardiovascular Agents; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Microsomes, Liver; Phosphodiesterase Inhibitors; Ritonavir; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2008 |
Darunavir: a review of its use in the management of HIV infection in adults.
Topics: Administration, Oral; Adult; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Meta-Analysis as Topic; Sulfonamides | 2009 |
HIV protease inhibitors: recent clinical trials and recommendations on use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolome; Oligopeptides; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides | 2009 |
[Safety and tolerability of etravirine].
Topics: Animals; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Drug Eruptions; Drug Evaluation, Preclinical; Dyslipidemias; Female; Fetus; Gastrointestinal Diseases; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Mental Disorders; Multicenter Studies as Topic; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides | 2009 |
Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2010 |
Protease inhibitor monotherapy.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cost-Benefit Analysis; Darunavir; Drug Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Ritonavir; Standard of Care; Sulfonamides | 2010 |
Pharmacoeconomics of darunavir.
Topics: Cost-Benefit Analysis; Darunavir; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Quality of Life; Quality-Adjusted Life Years; Ritonavir; Sulfonamides | 2011 |
Darunavir: an effective protease inhibitor for HIV-infected patients.
Topics: Darunavir; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Darunavir: a critical review of its properties, use and drug interactions.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides | 2012 |
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
[Protease inhibitors].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2005 |
Protease inhibitors: the current status.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Diarrhea; Dizziness; Drug Evaluation, Preclinical; Drug Therapy, Combination; Headache; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2005 |
Tribulations and trials in HIV disease, Part 2.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Sulfonamides | 2006 |
The clinical pharmacology of antiretrovirals in development.
Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2006 |
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Disease Progression; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Integrase Inhibitors; Male; Nitriles; Patient Compliance; Pyridazines; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Risk Assessment; Sulfonamides; United Kingdom | 2006 |
Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2006 |
When and how to use tipranavir and darunavir.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Interactions; HIV Infections; Humans; Pyridines; Pyrones; Sulfonamides; Viral Load | 2007 |
Development of therapeutics for AIDS: structure-based molecular targeting.
Topics: Acquired Immunodeficiency Syndrome; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Darunavir; Drug Design; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Sulfonamides | 2007 |
Darunavir: a second-generation protease inhibitor.
Topics: Animals; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2007 |
Darunavir (TMC114): a new HIV-1 protease inhibitor.
Topics: Controlled Clinical Trials as Topic; Darunavir; Drug Combinations; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Quality of Life; Ritonavir; Sulfonamides | 2007 |
Darunavir: a nonpeptidic antiretroviral protease inhibitor.
Topics: Administration, Oral; Animals; Cost-Benefit Analysis; Darunavir; Drug Administration Schedule; Drug Costs; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2007 |
Darunavir.
Topics: Clinical Trials as Topic; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2007 |
Darunavir: in the treatment of HIV-1 infection.
Topics: Clinical Trials as Topic; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Treatment Outcome | 2007 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2008 |
[New therapeutic options in protracted HIV-infected patients with virological failure].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Organic Chemicals; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides | 2008 |
Darunavir: pharmacokinetics and drug interactions.
Topics: Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2008 |
172 trial(s) available for darunavir and HIV Coinfection
| Article | Year |
|---|---|
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2021 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Topics: Adult; Cobicistat; Darunavir; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; RNA; United States; Viral Load | 2021 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Pyridones; Ritonavir | 2023 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans | 2023 |
Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.
Topics: Anti-HIV Agents; Darunavir; Female; HIV Infections; Humans; Infant, Newborn; Pregnancy; Ritonavir; Treatment Outcome; Viral Load | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tablets; Therapeutic Equivalency | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2020 |
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001
Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2020 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir | 2020 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; Treatment Outcome; Viral Load | 2020 |
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Topics: Anti-HIV Agents; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Quality of Life; Ritonavir; Viral Load | 2022 |
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
Topics: Anti-HIV Agents; Child; Cobicistat; Darunavir; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Placenta; Postpartum Period; Pregnancy; Prospective Studies | 2021 |
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Resistance; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult; Zidovudine | 2021 |
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Synergism; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Treatment Outcome; Young Adult | 2017 |
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Female; Half-Life; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Saliva; Young Adult | 2017 |
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Tandem Mass Spectrometry | 2017 |
Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Plasma; Prospective Studies; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr
Topics: Adult; Cobicistat; Darunavir; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2017 |
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Young Adult | 2018 |
CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Central Nervous System; Cognition; Darunavir; Drug Therapy, Combination; Executive Function; Female; Ferritins; HIV Infections; HIV-1; Humans; Magnetic Resonance Imaging; Male; Maraviroc; Middle Aged; Neopterin; Pilot Projects; Psychomotor Performance; Ritonavir; S100 Calcium Binding Protein beta Subunit | 2018 |
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Models, Statistical; Plasma; Raltegravir Potassium; Ritonavir; Viral Load; Young Adult | 2018 |
Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series.
Topics: Anti-HIV Agents; Darunavir; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Salvage Therapy; Viral Load | 2018 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunity, Cellular; Inflammation; Lopinavir; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Raltegravir Potassium; RNA, Viral; Viremia; Virus Replication | 2018 |
Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
Topics: Cell Line, Tumor; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Ritonavir | 2018 |
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Data Interpretation, Statistical; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2018 |
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2018 |
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Topics: Adult; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Plasma; Reverse Transcriptase Inhibitors; Ritonavir; Semen; Therapeutic Equivalency | 2018 |
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Risk Factors; Young Adult | 2018 |
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States | 2018 |
Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Tissue Distribution; Virus Shedding | 2019 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Medication Adherence; Tenofovir | 2018 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Disease Progression; Drug Substitution; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Maraviroc; Middle Aged; Ritonavir | 2019 |
Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
Topics: Adult; Cobicistat; Darunavir; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal Age; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Treatment Outcome | 2019 |
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Topics: Adult; Aged; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reproducibility of Results; Salvage Therapy | 2018 |
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; Darunavir; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2019 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
Topics: Adult; Age Factors; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Internet; Italy; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Time Factors; Viral Load | 2013 |
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Cross-Over Studies; Darunavir; Drug Interactions; Ethanolamines; Fluorenes; Healthy Volunteers; HIV; HIV Infections; Humans; Lumefantrine; Malaria; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2013 |
Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Ritonavir; Sulfonamides; Viral Load; Young Adult | 2013 |
Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Biological; Organic Anion Transporters; Polymorphism, Single Nucleotide; Ritonavir; Sulfonamides | 2013 |
Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Beclomethasone; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2013 |
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2013 |
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult | 2013 |
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Topics: Adolescent; Adult; Darunavir; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Sulfonamides; Young Adult | 2014 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2013 |
Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Bone Density; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome | 2014 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Proteins; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neopterin; Oligopeptides; Protein Binding; Pyridines; Ritonavir; RNA, Viral; Sulfonamides | 2014 |
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-HIV Agents; Creatinine; Darunavir; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Serum Albumin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Cytokines; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Lopinavir; Male; Middle Aged; Ritonavir; Sulfonamides; Viremia | 2014 |
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Topics: Adult; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Telomerase; Telomere | 2014 |
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.
Topics: Adult; Anti-Retroviral Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Plasma; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Topics: Adult; Aged; Anti-HIV Agents; Body Fat Distribution; Bone Density; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Topics: CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Meta-Analysis as Topic; Middle Aged; Nitriles; Odds Ratio; Pyridazines; Pyrimidines; Ritonavir; Spain; Sulfonamides; Switzerland; United Kingdom; Viral Load | 2015 |
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plasma; Ritonavir; Tandem Mass Spectrometry; Viral Load; Viremia; Young Adult | 2015 |
[Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2014 |
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
Topics: Anti-HIV Agents; Child; Child, Preschool; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Ritonavir | 2015 |
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir | 2015 |
Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Retreatment; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Darunavir; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Treatment Outcome | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
[In Process Citation].
Topics: Age Factors; Aged; Comorbidity; Cross-Sectional Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Raltegravir Potassium; Tenofovir | 2015 |
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy | 2015 |
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
Topics: Adult; Anti-HIV Agents; Bone and Bones; Bone Density; Calcifediol; Darunavir; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Ritonavir; Vitamin D | 2016 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Prospective Studies; Ritonavir; Semen; Viral Load; Young Adult | 2016 |
NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe).
Topics: CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HLA-DR Antigens; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Viral Load | 2016 |
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Ritonavir; Viral Load; Young Adult | 2016 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Topics: Adolescent; Darunavir; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult | 2017 |
Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Darunavir; Female; HIV Infections; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Tandem Mass Spectrometry; Young Adult | 2016 |
Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study.
Topics: Adult; Anti-HIV Agents; Cognition; Darunavir; Drug Substitution; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Ritonavir; Sleep | 2016 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Weight Gain | 2008 |
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Peptide Fragments; Ritonavir; Sulfonamides; Treatment Outcome | 2008 |
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Topics: Adult; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation, Missense; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
[Darunavir in treatment-naïve patients. The ARTEMIS study].
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Protease Inhibitors; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2009 |
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Logistic Models; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Topics: Adolescent; Child; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Patient Compliance; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Ritonavir; Sulfonamides | 2009 |
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2010 |
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load | 2010 |
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Middle Aged; Ritonavir; Sulfonamides | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Pilot Projects; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome | 2010 |
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Topics: Adult; Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
Topics: Adolescent; Adult; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Rifabutin; Ritonavir; Sulfonamides; Young Adult | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Topics: Darunavir; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Male; Plasma; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Sulfonamides | 2010 |
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Interactions; Echinacea; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Plant Extracts; Ritonavir; Sulfonamides | 2011 |
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pilot Projects; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Topics: Adult; Darunavir; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2011 |
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Costs; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2010 |
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Nitriles; Phenotype; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2011 |
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
Topics: Adult; Blood Glucose; Body Image; Body Size; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Lipids; Male; Middle Aged; Ritonavir; Sex Factors; Sulfonamides; Treatment Outcome | 2011 |
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Europe; Female; HIV Infections; Humans; Male; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure | 2011 |
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Odds Ratio; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2011 |
Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.
Topics: Adult; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Patient Compliance; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2011 |
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Young Adult | 2011 |
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2012 |
Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.
Topics: Adult; Darunavir; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Pyrones; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Prospective Studies; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
Topics: Adult; Body Fat Distribution; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2012 |
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Administration Schedule; HIV Infections; Humans; Male; Middle Aged; Ritonavir; Silybum marianum; Silymarin; Sulfonamides | 2012 |
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Topics: Adult; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Multidrug Resistance-Associated Protein 2; Polymorphism, Single Nucleotide; Ritonavir; Sulfonamides | 2012 |
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
Topics: Adult; Darunavir; DNA, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load; Viremia | 2012 |
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2013 |
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Protease Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2013 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Transport; Confidence Intervals; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Incidental Findings; Male; Membrane Transport Proteins; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2012 |
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Topics: Anti-HIV Agents; Darunavir; DNA, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides | 2013 |
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2005 |
Meeting notes from the 3rd IAS Conference. New drugs.
Topics: Brazil; CCR5 Receptor Antagonists; Congresses as Topic; Cytidine Triphosphate; Darunavir; HIV Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Zalcitabine | 2005 |
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Topics: Adult; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Data Interpretation, Statistical; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Predictive Value of Tests; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pyridines; Pyrones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Ritonavir; RNA, Viral; Statistics as Topic; Sulfonamides; Time Factors; Viral Load | 2007 |
Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; International Cooperation; Male; Middle Aged; Program Development; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2008 |
Resistance profile of darunavir: combined 24-week results from the POWER trials.
Topics: Adult; Amino Acid Substitution; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome | 2008 |
428 other study(ies) available for darunavir and HIV Coinfection
| Article | Year |
|---|---|
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
Topics: Amino Acid Sequence; Amino Acid Substitution; Binding Sites; Crystallography, X-Ray; Darunavir; DNA Mutational Analysis; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Polyproteins; Protein Binding; Protein Structure, Tertiary; Sulfonamides | 2009 |
Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
Topics: Antiretroviral Therapy, Highly Active; Cell Line; Crystallography, X-Ray; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genes, gag; Genes, pol; HEK293 Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Mutation; Peptide Fragments; pol Gene Products, Human Immunodeficiency Virus; Viral Load | 2012 |
Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Structure-Activity Relationship; Sulfonamides | 2015 |
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Topics: Benzothiazoles; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Pyrans; Structure-Activity Relationship; Sulfonamides | 2017 |
Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.
Topics: Amides; Crystallography, X-Ray; Drug Design; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Docking Simulation; Phthalic Acids | 2017 |
Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cell Line; Dimerization; Drug Development; HIV Infections; HIV-1; Humans; Models, Molecular; Prodrugs | 2020 |
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Topics: Crystallography, X-Ray; Darunavir; Dipeptides; Drug Design; Furans; HEK293 Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship | 2020 |
Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
Topics: 2-Propanol; Drug Design; HEK293 Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Phenols | 2020 |
Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.
Topics: Brain; Darunavir; HIV Infections; Humans; Matrix Metalloproteinase 9; Nanoparticles; Nervous System Diseases | 2021 |
Probing the interaction of anti-HIV drug Darunavir with dsDNA and HSA using electrochemical and spectroscopic measurements.
Topics: Anti-HIV Agents; Darunavir; DNA; Electrodes; HIV Infections; Humans; Serum Albumin, Human | 2021 |
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
Topics: Darunavir; DNA; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral | 2022 |
Mechanism of darunavir binding to monomeric HIV-1 protease: a step forward in the rational design of dimerization inhibitors.
Topics: Darunavir; Dimerization; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Mutation | 2022 |
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
Topics: Adult; Cobicistat; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Treatment Outcome | 2022 |
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Lopinavir; Quality of Life; Ritonavir; South Africa | 2022 |
Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA; Romania; Viral Load | 2022 |
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Europe; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; North America; Raltegravir Potassium; Rilpivirine | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Topics: Contraceptive Agents; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Progestins; Rilpivirine; Ritonavir | 2022 |
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir | 2023 |
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Infant; Milk, Human; Mothers; Prospective Studies; Raltegravir Potassium; Rilpivirine; Ritonavir; Switzerland | 2022 |
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Kazakhstan; Mutation; Nevirapine; Viral Load; Zidovudine | 2022 |
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load | 2023 |
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal.
Topics: Aging, Premature; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cellular Senescence; Darunavir; HIV Infections; HIV Protease Inhibitors; Mice; Ritonavir | 2023 |
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2022 |
Immune response to ART initiation in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunity; Tenofovir | 2023 |
Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Retrospective Studies; Ritonavir; Romania; Viral Load | 2023 |
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.
Topics: Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation | 2023 |
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Infant; Mutation; RNA; Viral Load | 2023 |
Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; Humans; Pyridones | 2023 |
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; RNA; Viral Load | 2023 |
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir".
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Seropositivity; HIV-1; Humans; Raltegravir Potassium; Ritonavir; RNA; Treatment Outcome; Viral Load | 2023 |
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2023 |
Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Raltegravir Potassium; Retrospective Studies; Salvage Therapy; Treatment Outcome; Viral Load | 2023 |
Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
Topics: Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; HIV Infections; Humans; Isoniazid | 2023 |
Atazanavir urolithiasis without recent intake of atazanavir.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Substitution; Hepatitis C; HIV Infections; Humans; Inactivation, Metabolic; Late Onset Disorders; Liver; Male; Time Factors; Urolithiasis | 2019 |
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).
Topics: Adult; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Viral Load | 2019 |
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Topics: Aged; Aged, 80 and over; Aging; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
Topics: Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2019 |
Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Male; Middle Aged; Mutation; Protease Inhibitors; Treatment Failure; Viral Load | 2019 |
Factors associated with the number of drugs in darunavir/cobicistat regimens.
Topics: Adult; Age Factors; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Spain; Viral Load | 2020 |
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Topics: Adult; Africa, Western; Algorithms; Clinical Decision-Making; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Raltegravir Potassium; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2019 |
Simplification of ART in a patient living with multidrug resistant HIV-1: A case report using twice daily cobicistat and darunavir.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Treatment Outcome | 2019 |
Are 96-week data enough for doravirine to DRIVE FORWARD?
Topics: Adult; Darunavir; Double-Blind Method; HIV Infections; HIV-1; Humans; Ritonavir | 2020 |
Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Atazanavir Sulfate; Carbamazepine; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Oxcarbazepine; Piperazines; Pyridones | 2020 |
Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy.
Topics: Cross-Sectional Studies; Darunavir; Female; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lipidomics; Lipids; Male; Middle Aged; Viral Load | 2019 |
Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.
Topics: Atazanavir Sulfate; Case-Control Studies; Child; Child, Preschool; Darunavir; Gene Deletion; HIV; HIV Infections; Humans; Myocardial Infarction; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses | 2020 |
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Topics: Adult; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Logistic Models; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Viral Load | 2020 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Topics: Adult; Aged; CD4 Lymphocyte Count; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2019 |
Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Topics: Adult; Atazanavir Sulfate; Case-Control Studies; Cohort Studies; Darunavir; Databases, Factual; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome | 2020 |
Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
Topics: Atazanavir Sulfate; Cardiovascular Diseases; Case-Control Studies; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Myocardial Infarction; Risk Factors | 2020 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Statistics as Topic; Young Adult | 2020 |
HIV-1 superinfection in a patient with known HIV-2 - A case report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Male; Middle Aged; Superinfection; Tenofovir; Treatment Outcome | 2020 |
Topics: Administration, Intravaginal; Animals; Biological Transport; Cell Line, Tumor; Darunavir; Disease Models, Animal; Drug Compounding; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Macaca fascicularis; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tenofovir; Tissue Distribution; Up-Regulation; Vagina | 2020 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Viral Load | 2020 |
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Retrospective Studies; Rilpivirine; Ritonavir; Spain; Viral Load | 2020 |
Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Coinfection; Comorbidity; Darunavir; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Retrospective Studies; Spain; Treatment Outcome; Viral Load | 2020 |
Cobicistat: A case of mislabelled drug-drug interaction risk?
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Interactions; Drug Labeling; HIV Infections; Humans; Pharmaceutical Preparations | 2020 |
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Darunavir; Female; Gastrointestinal Tract; HIV Infections; HIV-1; Humans; Ileum; Lymph Nodes; Male; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; San Francisco; Virus Replication | 2020 |
Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Topics: Anti-HIV Agents; Coinfection; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Oxazines; Phylogeny; Piperazines; Pyridones; RNA, Viral; Sexual and Gender Minorities; Syphilis; Treponema pallidum; Viral Load | 2020 |
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires | 2020 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Darunavir; HIV Infections; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Darunavir; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Tenofovir; Viral Load | 2020 |
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Topics: Darunavir; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Retrospective Studies; Ritonavir | 2020 |
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity.
Topics: Cell Line; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Virus Replication | 2020 |
Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Ritonavir | 2020 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
Topics: Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir | 2021 |
Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
Topics: Crystallography, X-Ray; Darunavir; Drug Design; Enzyme Inhibitors; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Molecular Structure; Piperidines; Structure-Activity Relationship; Sulfonamides | 2020 |
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; RNA, Viral; Treatment Outcome; Viral Load | 2020 |
Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Long-Term Survivors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Treatment Outcome; Viral Load | 2020 |
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.
Topics: Animals; Betacoronavirus; Cells, Cultured; Clinical Trials as Topic; Coculture Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Decidua; Disease Models, Animal; Drug Repositioning; Drug Therapy, Combination; Embryo Implantation; Endometrium; Female; HIV Infections; Humans; Lopinavir; Maternal Exposure; Mice; Pandemics; Placentation; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Primary Cell Culture; SARS-CoV-2; Trophoblasts; Vascular Remodeling | 2020 |
Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV.
Topics: Darunavir; HIV Infections; Humans; Lipids; Nanoparticles; Polymers; Ritonavir | 2020 |
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Topics: Aged; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Viral Load | 2020 |
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.
Topics: Adult; Age Factors; Aged; Betacoronavirus; Body Weights and Measures; Comorbidity; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A; Darunavir; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-6; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Monte Carlo Method; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Sex Factors | 2020 |
Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Homosexuality, Male; Humans; London; Male; Retention in Care; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2020 |
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Italy; Male; Middle Aged; Muscles; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors | 2020 |
Changes in weight and BMI with first-line doravirine-based therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2021 |
Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.
Topics: Adult; Aged; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Biological; Reproducibility of Results | 2021 |
Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.
Topics: Anti-HIV Agents; Argentina; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Raltegravir Potassium; Retrospective Studies; Ritonavir; Viral Load | 2021 |
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Topics: Adolescent; Child; Child, Preschool; Darunavir; Follow-Up Studies; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2021 |
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Osteogenesis; Oxazines; Piperazines; Pyridones | 2021 |
Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation.
Topics: Cobicistat; Darunavir; HIV Infections; Humans; Spectrophotometry; Tablets | 2021 |
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
Topics: Anti-HIV Agents; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2021 |
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles | 2021 |
Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Darunavir; Glomerular Filtration Rate; HIV Infections; Humans; Retrospective Studies | 2021 |
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Darunavir; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Plasma; Sweden | 2021 |
Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir.
Topics: Cushing Syndrome; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Iatrogenic Disease; Ritonavir | 2021 |
Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Topics: Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Hydrogen Bonding; Kinetics; Lopinavir; Molecular Dynamics Simulation; Mutation; Protein Stability; Recombinant Proteins; Thermodynamics; Treatment Failure | 2021 |
Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6".
Topics: COVID-19; Darunavir; HIV Infections; Humans; Interleukin-6; SARS-CoV-2 | 2021 |
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".
Topics: COVID-19; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-6; Ritonavir; SARS-CoV-2 | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy | 2021 |
Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Darunavir; Data Mining; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pharmacovigilance; Pregnancy; Pregnancy Complications; United States; United States Food and Drug Administration; Young Adult | 2021 |
Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Topics: Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Peptide Hydrolases | 2022 |
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Topics: Aged; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Cobicistat; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir | 2017 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Interdependence of Inhibitor Recognition in HIV-1 Protease.
Topics: Darunavir; Drug Design; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Conformation; Water | 2017 |
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Darunavir; Endothelial Cells; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load; Viremia | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; British Columbia; Canada; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2017 |
Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protein Binding; Raltegravir Potassium; Saliva; Tandem Mass Spectrometry; Tenofovir | 2017 |
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Conference on Retroviruses and Opportunistic Infections 2017 highlights.
Topics: AIDS-Related Opportunistic Infections; Amides; Anti-HIV Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Darunavir; Disease Management; Disease Susceptibility; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Penis; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Washington | 2017 |
Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Topics: Atazanavir Sulfate; Blood Proteins; Darunavir; Dose-Response Relationship, Drug; Female; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy; Protein Binding | 2017 |
Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
Topics: Cell Line; Cytochrome P-450 CYP3A; Darunavir; Ethanol; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Microsomes, Liver; Molecular Docking Simulation; Monocytes; Ritonavir; Virus Replication | 2017 |
Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.
Topics: Adult; Aged; Cross-Sectional Studies; Darunavir; Diet Surveys; Drug Therapy, Combination; Feeding Behavior; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Outpatients; Patient Education as Topic; Ritonavir; Young Adult | 2017 |
Antiretroviral therapies and cardiovascular risk: True or false?
Topics: Cardiovascular Diseases; Darunavir; HIV; HIV Infections; Humans; Risk Factors | 2017 |
Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases.
Topics: Adult; Darunavir; Female; Food-Drug Interactions; Garlic; HIV Infections; HIV Protease Inhibitors; Humans; Male | 2017 |
Darunavir-Loaded Lipid Nanoparticles for Targeting to HIV Reservoirs.
Topics: Amino Acid Sequence; Animals; Biological Availability; Caco-2 Cells; Darunavir; Drug Carriers; Drug Delivery Systems; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Nanoparticles; Particle Size; Permeability; Rats; Rats, Wistar; Tissue Distribution | 2018 |
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Risk factors contributing to a low darunavir plasma concentration.
Topics: Adult; Aged; Darunavir; Drug Monitoring; Female; Food-Drug Interactions; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Risk Factors; Young Adult | 2018 |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Viral Load | 2018 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia | 2018 |
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult | 2018 |
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Ritonavir; Viral Load; Young Adult | 2018 |
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2018 |
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load | 2018 |
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
Topics: Anti-HIV Agents; Antifungal Agents; Darunavir; Drug Interactions; Histoplasmosis; HIV Infections; Humans; Itraconazole; Male; Mental Disorders; Middle Aged; Plasma; Ritonavir | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Topics: Child; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Ritonavir | 2018 |
Symptomatic central nervous system viral escape in patient on darunavir monotherapy.
Topics: Darunavir; Encephalitis, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Viral Load; Virus Replication | 2018 |
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
Topics: Antiviral Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV-1; Peptide Hydrolases; Protease Inhibitors | 2018 |
Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada.
Topics: Adult; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Treatment Outcome; Viral Load | 2018 |
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Darunavir; Drug Dosage Calculations; Equivalence Trials as Topic; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir | 2018 |
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Belgium; Darunavir; Female; HIV Infections; Humans; Male; Retrospective Studies; Ritonavir | 2018 |
Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Semen; Semen Analysis; Viral Load | 2018 |
Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Topics: Administration, Oral; Animals; Darunavir; Drug Delivery Systems; HIV Infections; HIV Protease Inhibitors; HIV-1; Male; Nanoparticles; Rats; Rats, Sprague-Dawley; Ritonavir | 2018 |
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Topics: Adult; Atazanavir Sulfate; Australia; Cardiovascular Diseases; Darunavir; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Association of antiretroviral therapy with brain aging changes among HIV-infected adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Brain; Darunavir; HIV Infections; Humans; Middle Aged; Neurodegenerative Diseases; Ritonavir; Young Adult | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir | 2018 |
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bariatric Surgery; Chromatography, Liquid; Darunavir; Emtricitabine; Female; Gastric Bypass; HIV Infections; Humans; Obesity; Plasma; Tandem Mass Spectrometry; Tenofovir | 2018 |
Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2019 |
Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Topics: Anti-Retroviral Agents; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Quinolones | 2019 |
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Ritonavir | 2018 |
Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.
Topics: Adult; Aged; Bayes Theorem; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Netherlands; Outpatients; Young Adult | 2019 |
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
Topics: Adult; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2018 |
Different effects of glucocorticoids on darunavir plasma concentrations.
Topics: Cytochrome P-450 CYP3A; Darunavir; Drug Combinations; Drug Interactions; Glucocorticoids; HIV Infections; HIV Protease Inhibitors; Humans; Intervertebral Disc Displacement; Male; Methylprednisolone; Middle Aged; Prednisone; Trigeminal Neuralgia | 2019 |
Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Viral Load | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
A case of late presentation of darunavir-related cholestatic hepatitis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cholestasis, Intrahepatic; Darunavir; HIV Infections; HIV Protease Inhibitors; Homosexuality, Male; Humans; Male; Raltegravir Potassium; Treatment Outcome; Viral Load | 2019 |
Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; CD4-CD8 Ratio; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Function Tests; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Treatment Outcome; Viral Load | 2019 |
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Topics: Anti-HIV Agents; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2019 |
Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2019 |
Does less equal more yet?
Topics: Darunavir; HIV Infections; Humans; Lopinavir; Ritonavir; RNA | 2019 |
Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.
Topics: Adult; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2019 |
Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.
Topics: Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pyridones; Viral Load; Young Adult | 2019 |
Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Treatment Failure; Viral Load | 2019 |
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Viral Load | 2013 |
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People | 2013 |
Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Female; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Failure; Triazoles; Viral Load | 2013 |
Novel once-daily tablet against HIV.
Topics: Darunavir; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Tablets | 2013 |
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Crystallization; Darunavir; Female; HIV Infections; Humans; Male; Microscopy, Polarization; Middle Aged; Oligopeptides; Plasma; Pyridines; Sulfonamides; Urine; Young Adult | 2013 |
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.
Topics: Adult; Anti-HIV Agents; Biomarkers; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Lymphocyte Activation; Male; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; T-Lymphocytes; Viral Load | 2013 |
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Models, Economic; Prognosis; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.
Topics: Adult; Aged; Clinical Trials as Topic; Cross-Sectional Studies; Darunavir; Female; Gender Identity; Health Care Surveys; HIV Infections; HIV Protease Inhibitors; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Puerto Rico; Racial Groups; Ritonavir; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; United States; Viral Load | 2013 |
Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2013 |
[Reasons for the introduction of darunavir in the antirretroviral treatment in HIV-infected patients].
Topics: Adolescent; Adult; Age Factors; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Sex Factors; Socioeconomic Factors; Spain; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2013 |
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir.
Topics: Cushing Syndrome; Darunavir; Drug Interactions; Female; Glucocorticoids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Iatrogenic Disease; Injections, Intra-Articular; Middle Aged; Ritonavir; Shoulder Pain; Sulfonamides; Treatment Outcome; Triamcinolone | 2013 |
Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Darunavir; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Time Factors; Young Adult | 2013 |
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Topics: Adult; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; United States; Viral Load | 2014 |
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Cohort Studies; Darunavir; DNA, Viral; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Proviruses; Real-Time Polymerase Chain Reaction; Ritonavir; Sulfonamides; Viral Load; Viremia | 2014 |
Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis.
Topics: Antiviral Agents; Darunavir; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Plasma; Sulfonamides | 2014 |
Immune activation throughout a boosted darunavir monotherapy simplification strategy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Darunavir; Female; Fibrin Fibrinogen Degradation Products; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome | 2014 |
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2014 |
Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Retreatment; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2014 |
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus.
Topics: Ankle Fractures; Anticoagulants; Darunavir; Drug Interactions; Gastrointestinal Hemorrhage; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Morpholines; Ritonavir; Rivaroxaban; Sulfonamides; Thiophenes | 2014 |
Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.
Topics: Adult; Darunavir; Drug Combinations; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir; Sulfonamides | 2014 |
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2014 |
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Topics: Atazanavir Sulfate; Base Sequence; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Docking Simulation; Molecular Sequence Data; Mutation; Oligopeptides; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2014 |
FLAMINGO: how much rosier can antiretroviral therapy get?
Topics: Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Plasma exchange significantly affects darunavir exposure.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Plasma Exchange; Ritonavir; Sulfonamides; Viral Load | 2014 |
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
Topics: Adult; Africa South of the Sahara; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Darunavir; Drug Costs; Female; Health Resources; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Models, Theoretical; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Survival Analysis; Treatment Failure | 2014 |
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.
Topics: Adult; Algorithms; Antiviral Agents; Cells; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Monocytes; Peptide Hydrolases; Ritonavir | 2014 |
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Ritonavir; Sulfonamides; Young Adult | 2014 |
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Spain; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor.
Topics: Adult; Anti-Retroviral Agents; Darunavir; Exanthema; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Sulfonamides; Taiwan | 2014 |
Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.
Topics: Anti-HIV Agents; Apoptosis; Cells, Cultured; Cyclohexanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Neutrophils; Sulfonamides; Triazoles | 2014 |
Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
Topics: Animals; Anti-HIV Agents; Body Fluids; Cervix Uteri; Contraceptive Devices, Female; Darunavir; Disease Models, Animal; Disease Transmission, Infectious; Drug Therapy, Combination; Female; HIV Infections; Humans; Inhibitory Concentration 50; Macaca; Pre-Exposure Prophylaxis; Pyrimidines; Rectum; Sulfonamides; Uterus; Vagina | 2014 |
Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Topics: Adult; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Darunavir; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Ritonavir | 2014 |
Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV-1; Humans; Male; Mutation, Missense; Prospective Studies; Ritonavir; Sulfonamides | 2015 |
[HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2014 |
A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cognition Disorders; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Prospective Studies; Sulfonamides | 2014 |
Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Ritonavir; Sulfonamides | 2014 |
[Retinal folds as a non-reported secondary effect of darunavir in a 20 year-old HIV patient].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Levofloxacin; Meropenem; Ophthalmoscopy; Pneumonia, Pneumococcal; Polypharmacy; Retinal Dystrophies; Thienamycins; Young Adult | 2015 |
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Aspergillus; Darunavir; Drug Interactions; Emtricitabine; HIV Infections; HIV Protease Inhibitors; Humans; Lung Abscess; Male; Ritonavir; Tenofovir; Treatment Outcome; Voriconazole | 2015 |
[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].
Topics: AIDS Dementia Complex; Anti-Retroviral Agents; Central Nervous System; Cognition Disorders; Darunavir; Disease Progression; Drug Resistance, Viral; Drug Substitution; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viremia; Zidovudine | 2014 |
Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Synergism; HIV Infections; Humans; Lamivudine; Ritonavir; Sulfonamides; Treatment Outcome | 2015 |
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Child; Cholesterol; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Retrospective Studies; Sulfonamides | 2014 |
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.
Topics: Anti-Retroviral Agents; Coinfection; Cyclohexanes; Darunavir; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Triazoles | 2015 |
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Prevalence; United States | 2015 |
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Longitudinal Studies; Mutation; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load | 2015 |
Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.
Topics: Adult; Animals; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Italy; Male; Middle Aged; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2015 |
Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation; Nitriles; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Precursors; Pyridazines; Pyrimidines; Recombination, Genetic; Republic of Korea | 2015 |
Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study.
Topics: Adult; Aged; Body Mass Index; CD4-CD8 Ratio; Cholesterol; Cross-Sectional Studies; Darunavir; Diabetes Mellitus; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypertension; Male; Middle Aged; Prevalence; Survivors; Time Factors; Triglycerides; Young Adult | 2015 |
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
Topics: Adult; Bacterial Translocation; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; Viral Load; Viremia | 2015 |
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Sulfonamides; Young Adult | 2015 |
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Anti-Infective Agents; Case-Control Studies; Cohort Studies; Darunavir; Drug Hypersensitivity; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination | 2015 |
In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir.
Topics: Administration, Oral; Animals; Biological Availability; Darunavir; Drug Liberation; HIV Infections; Lipids; Nanoparticles; Rats | 2016 |
Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients.
Topics: Child; Child, Preschool; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2015 |
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides | 2015 |
Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Topics: Adult; Case-Control Studies; Coinfection; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ritonavir | 2015 |
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunophenotyping; Male; Middle Aged; Niacin; Pyridoxine; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes; Zinc Compounds | 2016 |
Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Topics: Adult; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Models, Biological; Pregnancy; Ritonavir; Young Adult | 2016 |
Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Darunavir; Female; Gene Expression; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; HLA-DR Antigens; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2016 |
[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].
Topics: Adult; Aged; Darunavir; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir | 2015 |
Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Bacterial Infections; Darunavir; Drug Hypersensitivity; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination | 2015 |
Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Europe; Female; HIV Infections; Humans; Male; Thailand | 2016 |
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Topics: Aged; Cell Survival; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Middle Aged; Molecular Structure; Mutation; Virus Replication | 2015 |
The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
Topics: Darunavir; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir | 2016 |
Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; Health Expenditures; Health Services; HIV Infections; Humans; Male; Medicaid; Medication Adherence; Middle Aged; Models, Econometric; Propensity Score; Retrospective Studies; Ritonavir; Socioeconomic Factors; United States | 2016 |
Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Hemodynamics; HIV Infections; HIV-1; Humans; Lipid Metabolism; Lipids; Raltegravir Potassium; Ritonavir; Treatment Outcome | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load | 2016 |
Cerebrospinal fluid viral escape and acute encephalitis in a patient on boosted protease inhibitor monotherapy.
Topics: Adult; Brain; Darunavir; Encephalitis, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Magnetic Resonance Imaging; Male; Ritonavir; Treatment Failure; Viral Load | 2016 |
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a pote
Topics: Biomarkers; Chromatography, High Pressure Liquid; Cohort Studies; Darunavir; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Limit of Detection; Male; Middle Aged; Nitriles; Prognosis; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2016 |
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Europe; Female; Genotyping Techniques; HIV Infections; HIV Protease; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prognosis; Treatment Outcome; Young Adult | 2016 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2016 |
FDA notifications. Once daily dosing of darunavir approved.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2011 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine | 2016 |
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Rilpivirine; Ritonavir; Young Adult | 2016 |
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2016 |
Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long Term Adverse Effects; Lopinavir; Male; Retrospective Studies; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Young Adult | 2016 |
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Topics: Anti-Retroviral Agents; Darunavir; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Observational Studies as Topic; Ritonavir; RNA, Viral | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Treatment Failure; Viral Load; Young Adult | 2017 |
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Atazanavir Sulfate; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Male; Prospective Studies; Raltegravir Potassium; T-Lymphocyte Subsets | 2016 |
Life-threatening digoxin toxicity due to drug-drug interactions in an HIV-positive man.
Topics: Darunavir; Digoxin; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Renal Insufficiency; Ritonavir | 2017 |
Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Male; Ritonavir; Semen; Viral Load | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2017 |
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Drug Resistance, Viral; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retreatment; Ritonavir; RNA, Viral; Salvage Therapy; Viral Load; Virus Replication; Young Adult | 2017 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Mexico; Middle Aged; Prospective Studies; Pyridines; Pyrones; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2016 |
Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
Topics: Adult; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Polymorphism, Genetic; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2016 |
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; United Kingdom; Young Adult | 2016 |
[Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Topics: Adult; Cobicistat; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Prospective Studies; Ritonavir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Topics: Atazanavir Sulfate; Darunavir; DNA Replication; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Virus Replication; Zambia | 2016 |
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Young Adult | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Uganda; Young Adult | 2016 |
[Darunavir in special situations].
Topics: Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Male; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2016 |
[Present and future of darunavir for the treatment of human immunodeficiency virus infection].
Topics: Clinical Trials as Topic; Darunavir; Drug Combinations; Forecasting; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
Topics: Antirheumatic Agents; Antitubercular Agents; Cells, Cultured; Cobicistat; Darunavir; Drug Interactions; Drug Therapy, Combination; Hepatocytes; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Mycobacterium tuberculosis; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2017 |
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Nitriles; Patient Compliance; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Virus Replication | 2008 |
FDA alerts doctors to Prezista's possible link to liver damage, deaths.
Topics: Chemical and Drug Induced Liver Injury, Chronic; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Sulfonamides; United States; United States Food and Drug Administration | 2008 |
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Pyridines; Pyrones; Sulfonamides; Treatment Failure; Viral Load | 2008 |
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Topics: Darunavir; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Time Factors | 2008 |
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
Topics: Amino Acid Sequence; Darunavir; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV-1; Humans; Longitudinal Studies; Male; Molecular Sequence Data; Mutation, Missense; Selection, Genetic; Sulfonamides | 2008 |
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
Topics: Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2008 |
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides; Virus Replication | 2008 |
[Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Sulfonamides; Viral Load | 2008 |
[HIV therapy and adherence].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Patient Compliance; Prognosis; Pyridines; Pyrones; Sulfonamides | 2008 |
Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome | 2008 |
Use of darunavir and enfuvirtide in a pregnant woman.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Peptide Fragments; Pregnancy; Pregnancy Outcome; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
FDA approves darunavir.
Topics: Adult; Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; United States; United States Food and Drug Administration | 2008 |
FDA notifications. Darunavir label has these changes.
Topics: Animals; Darunavir; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration; Viral Load | 2008 |
Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.
Topics: Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridines; Pyrones; Sulfonamides; Treatment Failure | 2009 |
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Topics: Amino Acid Substitution; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation, Missense; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
Topics: Adult; Aged; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Sulfonamides; Treatment Outcome | 2009 |
[Introduction. Darunavir].
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2008 |
[Position of darunavir in antiretroviral therapy].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2008 |
FDA notifications. FDA OKs new pediatric dosing for darunavir.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration; Viral Load | 2009 |
FDA notifications. New 600 mg tablet strength for darunavir is approved by FDA.
Topics: Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Tablets; United States; United States Food and Drug Administration | 2008 |
FDA notifications. Tibotec issues Dear Health Care Professional letter.
Topics: Darunavir; Drug Industry; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Sulfonamides; United States; United States Food and Drug Administration | 2008 |
Transplacental passage of ritonavir-boosted darunavir in two pregnant women.
Topics: Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2008 |
Darunavir now approved for use in treatment-naive patients.
Topics: Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States | 2008 |
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.
Topics: Adult; Chromatography, Liquid; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mass Spectrometry; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.
Topics: Adult; Anti-Retroviral Agents; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Protease Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides; Tacrolimus | 2009 |
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
Topics: Adolescent; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Darunavir; Enfuvirtide; Guideline Adherence; Guidelines as Topic; Health Plan Implementation; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Sulfonamides | 2009 |
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Prezista fares better than Kaletra in first line therapy.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Sulfonamides; Viral Load | 2009 |
Hypersensitivity reaction to darunavir and desensitization protocol.
Topics: Adolescent; Anti-Infective Agents; Darunavir; Desensitization, Immunologic; Drug Hypersensitivity; Female; HIV Infections; Humans; Sulfonamides | 2009 |
Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient.
Topics: Darunavir; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Sulfonamides; Treatment Outcome | 2009 |
Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Darunavir; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; Male; Risk Factors; Stevens-Johnson Syndrome; Sulfonamides; Treatment Outcome | 2009 |
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
[Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunocompetence; Interleukin-2; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Triazoles; Viral Load | 2009 |
Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Topics: Ambulatory Care Facilities; Anti-Retroviral Agents; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Approval; Drug Prescriptions; Electronic Health Records; Female; Health Facility Size; HIV Infections; Humans; Male; Oligopeptides; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Food and Drug Administration; Veterans | 2010 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.
Topics: Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2010 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
Topics: Adolescent; Child; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2010 |
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in t
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load | 2010 |
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
Topics: Algorithms; Amino Acid Substitution; Cohort Studies; Darunavir; Databases, Factual; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Multivariate Analysis; Mutation; Phenotype; Pyridines; Pyrones; Quebec; Sulfonamides | 2010 |
Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
Topics: Darunavir; Databases, Factual; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Pyridines; Pyrones; Spain; Sulfonamides | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir | 2010 |
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
Topics: Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Salvage Therapy; Sulfonamides | 2010 |
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2011 |
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
FDA notifications. Labeling changed on Prezista.
Topics: Clinical Trials as Topic; Darunavir; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected men.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Male; Middle Aged; Semen; Sulfonamides | 2010 |
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Dimerization; Drug Design; Drug Resistance, Multiple, Viral; Furans; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Proteins; Structure-Activity Relationship; Sulfonamides | 2010 |
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Darunavir; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Topics: Bayes Theorem; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Topics: Adolescent; Adult; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2010 |
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome | 2010 |
Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Depression; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; HIV Infections; HIV Protease Inhibitors; Humans; Male; Piperazines; Quinolones; Ritonavir; Sulfonamides; Thiophenes | 2010 |
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
Topics: Adult; Algorithms; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Prognosis; Retrospective Studies; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Darunavir/ritonavir monotherapy in clinical practice.
Topics: Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.
Topics: Adult; Anti-HIV Agents; Brain; Brain Diseases, Metabolic; Darunavir; Female; HIV Infections; Humans; London; Male; Nucleosides; Prospective Studies; Ritonavir; Sulfonamides | 2011 |
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.
Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; United States; Young Adult | 2010 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Markov Chains; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom | 2010 |
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Disease Progression; Drug Resistance; Female; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; United States; Viral Load; Young Adult | 2010 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Darunavir; Drug Resistance, Viral; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Lopinavir; Male; Markov Chains; Multicenter Studies as Topic; Pyrimidinones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom; Viral Load | 2010 |
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Darunavir; Drug Costs; Europe; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; United States; Young Adult | 2010 |
Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
Topics: Adult; Antiretroviral Therapy, Highly Active; Budgets; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Darunavir; Drug Costs; Drug Resistance; France; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Analysis of resistance testing in South Trinidad.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Organophosphonates; Patient Compliance; Sulfonamides; Tenofovir; Trinidad and Tobago | 2010 |
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacolog
Topics: Adolescent; Adult; Aged; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Retrospective Studies; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2012 |
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Topics: Anti-HIV Agents; Darunavir; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Peptide Fragments; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2011 |
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Mutation; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Sulfonamides; Treatment Failure | 2011 |
Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.
Topics: Adult; Anti-Retroviral Agents; Darunavir; Hemodiafiltration; HIV Infections; Humans; Male; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome | 2011 |
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
Topics: Algorithms; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Predictive Value of Tests; Ritonavir; Sulfonamides; Treatment Outcome | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
Topics: Darunavir; Drug Resistance, Viral; Enfuvirtide; Genotype; HIV; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Logistic Models; Peptide Fragments; Point Mutation; Sulfonamides | 2011 |
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Topics: Cell Line; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Sulfonamides | 2011 |
Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Sulfonamides; Viral Load | 2011 |
Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure | 2012 |
Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Pyridines; Pyrones; Sulfonamides; Taiwan; Treatment Failure | 2011 |
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral | 2012 |
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles | 2012 |
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Topics: Adult; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Pilot Projects; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure | 2012 |
Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
Topics: Antiretroviral Therapy, Highly Active; Budgets; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Spain; Sulfonamides | 2012 |
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides | 2012 |
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
Topics: Anti-HIV Agents; Child; Darunavir; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Prevalence; Sulfonamides; United Kingdom | 2012 |
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India; Male; Mutation, Missense; Sulfonamides; Viral Load; Viral Proteins | 2012 |
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; RNA, Viral; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load | 2012 |
Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; C-Reactive Protein; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Interleukin-6; Male; Ritonavir; Sulfonamides; Time Factors | 2012 |
[Status of anti-HIV drug development and an overview of combined chemotherapy].
Topics: Anti-HIV Agents; Darunavir; Drug Discovery; Drug Therapy, Combination; HIV Infections; Humans; Pyrrolidinones; Raltegravir Potassium; Sulfonamides | 2009 |
High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.
Topics: CD4 Lymphocyte Count; Child; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Prescription Drug Misuse; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Ritonavir; Sulfonamides | 2012 |
Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
Topics: Adult; Cohort Studies; Darunavir; Fasting; Genotyping Techniques; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipid Metabolism; Male; Middle Aged; Retrospective Studies; Ritonavir; Safety; Sulfonamides | 2012 |
Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Darunavir; Female; HIV Infections; Humans; Male; Ritonavir; Sulfonamides | 2012 |
[HIV therapy of the next generation. Modern active drugs for long-term treatment].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Long-Term Care; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sulfonamides | 2012 |
Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years.
Topics: Adolescent; Area Under Curve; Asian People; Body Weight; Child; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Metabolic Clearance Rate; Ritonavir; Sulfonamides; Thailand; Time Factors | 2012 |
Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; India; Mutation, Missense; Sulfonamides | 2013 |
A probable interaction between warfarin and the antiretroviral TRIO study regimen.
Topics: Anticoagulants; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; International Normalized Ratio; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides; Venous Thrombosis; Warfarin | 2012 |
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.
Topics: Anti-HIV Agents; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Protein Binding; Proteins; Specimen Handling; Sulfonamides; Tandem Mass Spectrometry; Ultrafiltration | 2013 |
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient.
Topics: Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Coinfection; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Darunavir; Depression; Drug Interactions; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Polymorphism, Single Nucleotide; Ritonavir; Serotonin Syndrome; Sulfonamides | 2012 |
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles | 2013 |
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2013 |
New PI may offer hope to triple class patients.
Topics: Clinical Trials, Phase II as Topic; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Sulfonamides | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
[New drugs--hope for salvage patients?].
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drugs, Investigational; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyrimidines; Receptors, Chemokine; Rilpivirine; Salvage Therapy; Sulfonamides; Treatment Failure | 2005 |
Report from the 13th retrovirus conference. New data on TMC114 and TMC125.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Sulfonamides; Viral Load | 2006 |
Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Failure; Viral Load | 2006 |
FDA approval: darunavir.
Topics: Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; Sulfonamides; United States; United States Food and Drug Administration | 2006 |
FDA clears HIV drug for patients with resistant virus.
Topics: Darunavir; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2006 |
Darunavir (Prezista) for HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Biological Availability; Blood Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Approval; Drug Interactions; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Peptide Fragments; Protein Binding; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Tablets; Time Factors; United States; Viral Load | 2006 |
TMC114 approved for resistant patients.
Topics: Darunavir; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2006 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |
The latest in antiretroviral therapy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles | 2006 |
Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Topics: Darunavir; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Peptide Fragments; Ritonavir; Sulfonamides | 2007 |
Darunavir: promising initial results.
Topics: Clinical Trials as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2007 |
Prezista gets EU approval.
Topics: Clinical Trials, Phase III as Topic; Darunavir; Drug Approval; Europe; European Union; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2007 |
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load | 2007 |
48-week study results show DRV's staying power.
Topics: Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load | 2007 |
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Topics: Adult; Anti-Retroviral Agents; Area Under Curve; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
No patient left behind--better treatments for resistant HIV infection.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Viral Load | 2007 |
Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans | 2007 |
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
Topics: Amino Acid Substitution; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Spain; Sulfonamides | 2007 |
Predicting HIV care costs using CD4 counts from clinical trials.
Topics: Adult; Alabama; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Multivariate Analysis; Primary Health Care; Ritonavir; Student Health Services; Sulfonamides | 2007 |
Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials, Phase IV as Topic; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Patient Selection; Pyridines; Pyrones; Research Design; Sulfonamides; Viral Load | 2007 |
Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Topics: Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.
Topics: Alkynes; Benzoxazines; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; Darunavir; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reference Standards; Reproducibility of Results; Solutions; Sulfonamides | 2007 |
Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Topics: Cross-Over Studies; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Pyrones; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Defining HIV susceptibility to new antiretroviral agents--darunavir.
Topics: Darunavir; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Protease Inhibitors; Sulfonamides | 2007 |
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
Topics: California; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Mutation; Prevalence; Protease Inhibitors; Retrospective Studies; Sulfonamides | 2007 |
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Darunavir; Drug Stability; HIV Infections; Humans; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides | 2007 |
Darunavir phase 3 study data released.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Evaluating the potency of HIV-1 protease drugs to combat resistance.
Topics: Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Mutation; Predictive Value of Tests; Sulfonamides | 2008 |
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Topics: Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Selection, Genetic; Sulfonamides; Treatment Failure | 2008 |
Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Darunavir in the treatment of HIV-1 infection: a viewpoint by Renslow Sherer.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Topics: Animals; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Lipodystrophy; Lopinavir; Membrane Proteins; Metabolic Syndrome; Metalloendopeptidases; Mice; Mice, Knockout; Nuclear Proteins; Protein Precursors; Protein Processing, Post-Translational; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
Topics: Chi-Square Distribution; Darunavir; Drug Resistance, Viral; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Logistic Models; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2008 |
[New drugs for HIV infection].
Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2008 |
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome | 2008 |